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8DEFINITIONS AND ABBREVIATIONS
DEFINITIONS 
Antepartum: An event happening before labor. 
Chronic hypertension:  Pre-pregnancy blood pressure of 140 mmHg systolic or 
90 mmHg diastolic or increased blood pressure 
diagnosed before 20 weeks of gestation. 
Early neonatal mortality:  Neonatal death within 7 days of birth. 
Eclampsia:    Preeclampsia with seizures. 
Fetal death, Papers I-III:  Birth of a dead fetus 16 weeks of gestation. 
Fetal death, Paper IV:  Birth of a dead fetus 20 weeks of gestation. 
Gestational hypertension:  Increase in maternal blood pressure to 140/90 mmHg 
after completed 20 weeks of gestation. 
Intrapartum:  An event happening during labor. 
Perinatal mortality rate, 
Papers II and IV:  Sum of infant deaths in pregnancies lasting 22 weeks 
(154 days) and within 7 days of birth, per 1000 births.  
Pre-eclampsia:  Increase in maternal blood pressure of >140/90 mmHg 
combined with proteinuria after completed 20 weeks of 
gestation, measured on at least two occasions 6 hours 
apart. 
Stillbirth, Paper II:   Birth of a dead fetus 22 weeks of gestation. 
9ABBREVIATIONS 
BMI     Body mass index 
CASP    Critical Appraisal Skills Programme 
CI     Confidence interval  
HR    Hazard ratio 
ICD-10   International Classification of Diseases Revision 10 
IgM     Immunoglobulin M 
IgG     Immunoglobulin G 
IUGR    Intrauterine growth restriction 
LMP    Last menstrual period 
MBRN   The Medical Birth Registry of Norway 
OR     Odds ratio  
PCR    Polymerase chain reaction 
PVB    Human parvovirus B19  
PMR    Perinatal mortality rate 
RCT    Randomized controlled trial 
RR    Relative risk (risk ratio in Paper IV) 
SES    Socioeconomic status 
SGA    Small for gestational age 
SPSS    Statistical Package for the Social Sciences
T. gondii    Toxoplasma gondii 
WHO    World Health Organization 
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1. INTRODUCTION 
In Norway more than 200 infants >22 weeks of gestation are stillborn each year.1 The 
global health impact of stillbirth is large, it is estimated that there are more than 2 
million stillbirths annually. However, the true number is probably higher, as 
underreporting is common.2;3 During the last 50 years stillbirth rates have declined in 
high-income countries, and the majority of cases (>98%) now happen in low- to 
middle-income countries.4 This reduction can be attributed to improvements in public 
health, and in medical and antenatal care.  
In Norway the late fetal mortality rate (>28 weeks of gestation) dropped from around 
40 per 1000 births in 1850 to 2 per 1000 births in 2012.1;5 Most of this decline 
happened between 1950 and 1980, but recently it has slowed.6;7 In high-income 
countries fetal mortality rates have stagnated, and sometimes risen,8;9 though these 
phenomena seem to be region-specific. In some regions this may be due to an 
increased prevalence of certain risk factors (i.e. advanced maternal age, obesity, 
multiple pregnancies) for fetal death in women of childbearing age,10 while in others 
the availability of prenatal diagnostics and induced termination of pregnancies may 
be the explanation.11  
Causes of fetal death are complex and incompletely understood. Etiological studies 
reported that between 9% and 60% of fetal deaths are unexplained, that is, no 
maternal, fetal, placental or obstetric cause could be found.12-17 Norwegian studies 
reported between 19% and 43% of stillbirths as unexplained.16;18;19 Differences in the 
proportion of stillbirths classified as unexplained are due to variations in the extent of 
the investigations performed after fetal death, but are also dependent on the 
classification system applied.10;20 In order to prevent fetal death, it is imperative to 
achieve a better understanding of its causes and risk factors. In order to inform 
preventive initiatives, caregivers and governments are reliant on relevant studies.  
Nearly 30 years ago, Yudkin and colleagues reported that the risk of fetal death 
varied by gestational age, increasing gradually with increasing gestational age.21
Recent studies have reported that the causes of fetal death also vary by gestational 
age.13;22 As distribution of causes vary by gestational age, risk factors may also 
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contribute differently to risk of fetal death depending on gestational age. Interaction 
between certain risk factors for fetal death such as maternal age,23 racial disparity,24
and educational level25 and gestational age has been implied, but needs to be further 
explored.  
Furthermore, it is widely accepted that stillbirths may be prevented by selective, 
timely elective delivery of fetuses at risk of death, however, the outcome of this 
intervention is dependent on gestational age. This concept has contributed to a left-
shift in the population distribution of gestational age at birth by increasing the number 
of iatrogenic premature births,26 but at the same time decreasing the stillbirth rate. 
The timing of delivery in pregnancies with increased risk of stillbirth is thus 
challenged by the competing risks of neonatal morbidity (neurodevelopmental 
impairments, respiratory distress, and gastrointestinal complications) associated with 
preterm birth.27  
In addition, studies of gestational-age-specific risk may guide clinicians on when to 
initiate antenatal care, and add to the knowledge on the pathological processes 
leading to stillbirth.  
The overall aims of this thesis were to study how the fetal mortality rate varies across 
gestation and over time in the Norwegian population. The findings should advance 
the understanding of fetal death, and at the same time evaluate the Norwegian 
healthcare system.   
In the following sections a definition of fetal death/stillbirth is given followed by a 
comprehensive review of the literature on certain risk factors for stillbirth and a brief 
overview of causes and consequences of stillbirth. 
1.1 Definition of fetal death/stillbirth 
The World Health Organization (WHO) in its International Classification of Diseases 
Revision 10 (ICD-10) defines fetal death as:  
“Death prior to the complete expulsion or extraction from its mother of a product of 
conception, irrespective of the duration of pregnancy; the death is indicated by the 
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fact that after such separation the fetus does not breathe or show any other evidence 
of life, such as beating of the heart, pulsation of the umbilical cord, or definite 
movement of voluntary muscles”.28
The WHO further distinguishes between early fetal deaths/stillbirths (death of a fetus 
with a birth weight >500 g, if birth weight not available gestational age >22 weeks or 
crown-heel length >25 cm) and late fetal deaths/stillbirths (death of a fetus with a 
birth weight >1000 g, if birth weight not available gestational age >28 weeks or 
crown-heel length >35 cm) (Figure 1).  
In the United States and Canada fetal death are categorized into early fetal death 
(20-27 weeks of gestation) and late fetal death (>28 weeks of gestation). Stillbirth 
categorization may also be based on timing of death in relation to labor; antepartum 
(prior to onset of labor) and intrapartum (during labor). The majority of stillbirths in 
high-income countries are antepartum.29
  
Figure 1.  Defining stillbirths and associated pregnancy outcomes. 
Reprinted from The Lancet 2011;377 (9775):1448-63.29  
Copyright (2011), with permission from Elsevier.
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Stillbirth is the informal term that covers both early and late fetal deaths.30 The term 
“stillbirth” originates from the eighteenth century, and was applied to fetuses born 
without movement (still, but not necessarily lifeless). During the early twentieth 
century, the definition was further refined to “stillbirth is birth of a viable fetus born 
dead”, and 28 weeks of gestation was set as the limit of viability.31 The fetal period 
begins at 10 weeks of gestation, and therefore fetal deaths comprises some 
miscarriages as well, whereas the term stillbirth is more commonly applied to fetal 
death occurring at >22 weeks of gestation.32  
The WHO recommends that late fetal deaths (>28 weeks) should be reported to 
assure global comparability, as countries where most fetal deaths occur do not have 
reliable data on early fetal deaths, and the chance for survival prior to 30 weeks of 
gestation in these countries is very limited.33;34 Whereas, in high-income countries the 
gestational age for neonatal survival has greatly decreased, as fetuses delivered as 
early as gestational week 22 may survive, and therefore in these countries early fetal 
deaths are more commonly registered.35 However, as can be seen in Table 1, the 
gestational age threshold applied for reporting fetal death in high-income countries 
varies, making international comparison challenging.36 The quality of the data in 
national vital registries also varies due to local legal definitions, and varying social, 
economic and cultural factors.37
In Norway, as per legal requirements passed in 1999, all fetal deaths occurring at 
>12 weeks of gestation are to be reported to the Medical Birth Registry of Norway 
(MBRN). The Norwegian Institute of Public Health publishes both early (gestational 
age 22-27 weeks) and late (gestational age >28 weeks) fetal death statistics.1  
In the present thesis the terms fetal death and stillbirth will be applied 
interchangeably, and this thesis will only focus on fetal death >16 weeks of gestation. 
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Table 1. Reporting requirements for fetal death in different countries.37-39
Lower 
gestational 
week 
Body 
length Birthweight Country Year 
>28 >35cm   League of Nations* 1925 
>28 >35cm >1000 g WHO 1950 
>28     United Kingdom 1926-1992 
>28   Sweden, Luxembourg   
    Greece, Iceland   
      Denmark -2003 
>26   Italy, Spain   
>24   United Kingdom, Hungary   
    Scotland, Portugal, Ireland   
>22 >25cm >500 g ICD-9 1975 
 >22   >500 g ICD-10 1992 
   Denmark,  2004 
    Latvia, Lithuania, France   
    Finland, Switzerland   
>20  350 g United States**   
      Canada 1959 
>20  400 g Australia   
      New Zealand   
   500 g Belgium, Germany,    
    Poland, Austria, Slovenia   
>16     Norway 1967-1998 
>12   Norway 1999 
* Precursor to the United Nations 1919-1947. 
** Most States 
Abbreviations: ICD-9. International Classification of Diseases Revision 9: ICD-10. International 
Classification of Disease Revision 10
1.2  Scope of fetal death 
The WHO reported global stillbirth (>28 weeks) estimates of approximately 4.3 million 
in 1995 (stillbirth rate 29 per 1000 births).40 A declining global trend has been 
reported with 3.3 million stillbirths in 2000 (stillbirth rate 24 per 1000 births), and 3 
million in 2004 (stillbirth rate 22 per 1000).41;42 Stanton and colleagues reported 
similar estimates for the year 2000 with 3.2 million (95% confidence interval [CI] 2.5-
4.1) stillbirths at >28 weeks of gestation, corresponding to a stillbirth rate of 23.9 
stillbirths per 1000 births (18.8-30.5).4 The latest global estimate of 2.6 million 
stillbirths in 2009 (stillbirth rate 18.9 per 1000) shows that there has been a 
continuing gradual decline in the number of stillbirth.2    
16
However, as can be seen in Figure 2, large global differences in the stillbirth rate 
prevail. Even across high-income countries the stillbirth rate (>28 weeks of gestation) 
differs and has been reported to range between 1.7 per 1000 births in Slovak 
Republic to 4.9 per 1000 births in France in 2004,43 and in 2009 between 1.5 per 
1000 births in Czech Republic and 4.3 per 1000 in France.44 When lower gestational 
age stillbirths (<28 weeks of gestation) are included in the estimates the inter-country 
differences increases from less than 4 to more than 8 stillbirths per 1000 births (some 
of the difference is due to registration of terminations of pregnancy as stillbirth in 
some countries). Also intra-country differences in stillbirth rates are reported and 
have been linked to accumulation of risk factors in deprived neighborhoods.45  
Although the stillbirth rate has declined the above described inequalities in the 
incidence indicates that further improvement is achievable.14
17
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2. SYSTEMATIC REVIEW OF THE LITERATURE ON RISK FACTORS FOR 
STILLBIRTH 
In this section a systematic review of observational studies was conducted, to 
explore the association between the most frequently reported risk factors in relation 
to stillbirth. 
Literature search
Relevant studies were identified by a systematic search of the peer-reviewed 
literature covering the period January 1990 to December 2013. A literature search 
using Medline (Ovid and PubMed) was undertaken using the following terms: 
“stillbirth” or “fetal death” or “fetal mortality” or “pregnancy outcome”, during the 
period 2003-2007, using a sensitive filter for the detection of etiological studies. For 
the period 1990-2002 and 2008-2013, a literature search using the Clinical Queries 
feature in PubMed for the terms “stillbirth” or “fetal death” was conducted, using a 
sensitive/broad filter for etiological studies. The reference lists of the obtained 
literature and current reviews were scrutinized for additional relevant publications. 
Study inclusion and exclusion criteria
Studies that fulfilled the following requirements were included: the main focus of the 
study was stillbirth (>20 weeks of gestation), at least one risk factor for stillbirth was 
assessed and the study was conducted in high-income countries (defined for the 
purpose of this review according to the Word Bank country classification: high-
income members of the Organization for Economic Co-operation and 
Development).46 The search was limited to publications in the English language and 
concerning human studies. 
The review was limited to the following risk factors associated with stillbirth: maternal 
demographic factors (maternal age, parity, socioeconomic status (SES), 
race/ethnicity), maternal lifestyle/behavioral factors (maternal weight, smoking, 
alcohol and coffee consumption), maternal medical disorders (hypertensive 
disorders, diabetes), pregnancy-related factors (intrauterine growth restriction 
(IUGR), gestational age, previous stillbirth).  
Studies were excluded if: a) stillbirth was not the main focus, b) the study only 
reported on intrapartum deaths, c) the study reported only perinatal deaths 
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 and stillbirths were not reported separately, d) the study was assessed to have low 
quality. The quality of the papers was assessed by applying the Critical Appraisal 
Skills Programme (CASP) checklist for observational studies available at the CASP 
UK website.47 The checklist is comprised of 12 questions enabling assessment of the 
methods used, validity of results, possible bias, confounding factors and 
generalizability.  
Results
A total of 10,910 publications were initially identified (Figure 3). After the review a 
total of 150 papers met the inclusion criteria; 128 cohort studies (22 prospective and 
106 retrospective), 19 case-control studies and three cross-sectional studies. In the 
following sections the results of the review is presented (Table 3).    
Figure 3. Inclusion and exclusion of studies for review.  
10 910 Papers identified by initial search  
386 Full papers retrieved  
10524 Papers excluded  
 (Reviews, case reports, letters, fetal 
death not studied, low- and medium-
income countries, duplicates) 
150  Finally included in the review  
248 Papers excluded  
 (Fetal death not main focus, low 
quality, only report perinatal 
mortality, twins, trends, only 
intrapartum deaths, double 
publication or same population) 
12 Further searches  
20
2.1 Maternal age 
The demographic distribution of pregnant women has increasingly shifted to the right 
in most high-income countries.48 In Norway the proportion of childbearing women 
aged 35 years or older has increased from 5.6% in 1978 to 19.5% in 2012, 
accordingly in the United States the proportion changed from 4.5% to 14.9% during 
the same period.1;23;49
High maternal age at childbearing is consistently associated with an increased risk of 
fetal death and the risk increases more with advancing age above 35 years (35-39 
years (odds ratio (OR) 1.3-2.0) and >40 years (OR 1.7-3.4)) as reported in the 
reviewed hospital-based50-53 and large population-based cohort studies (Table 
3).23;54-69 However, the OR varies between studies, and some of the most recent 
studies do not report an increased risk among women aged 35-39 years.53;69;70   
The cause of this increased risk remains unclear. Older women have a higher 
prevalence of medical conditions (hypertension, diabetes)52;54;56;57;61 and of 
complications during pregnancy (preterm births, small for gestational age 
(SGA)52;56;57;61 births). However, even after adjustment for these confounding factors 
the increased risk remains statistically significant,54;56;60 indicating that increased 
maternal age is independently associated with increased risk of fetal death.  
The incidence of fetal anomalies increases with maternal age,71 however, detection 
and termination of anomalous fetuses have resulted in decreased impact of this 
cause in recent times.51  
Contemporary older mothers have higher SES are more educated and have lower 
parity compared to older mothers a few decades ago, still the association with fetal 
death remains significant.62  
  
Gestational age is an effect modifier of the relative risk (RR) of fetal death in older 
women,23;60;64-66 as the risk of fetal death compared to younger women increases 
throughout pregnancy with the highest risk at term and post term.  
Studies of young maternal age (<19 years) and fetal death are inconsistent, reporting 
both an increased risk,54;58;67;72-74 and no increased risk.55;75;76 Large population-
based studies, most from the United States, display higher fetal mortality rates in 
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women aged <19 years compared to older women, with an OR varying between 1.05 
and 1.76.54;55;58;59;72 However, when analyses are adjusted for sociodemographic 
factors,55;59 and preterm birth,72 the OR is no longer significantly increased in most 
studies. In the largest study of teenage pregnancies to-date (5.8 million births to girls 
aged 15-19 years), Salihu and colleagues reported that the OR of fetal death in girls 
aged 15-19 years became insignificant relative to women aged 20-24 years, only 
when preterm birth was included in the multivariable model.72 Hence, the mechanism 
involved in fetal death in teenage pregnancies may be different than that among 
older women, involving higher occurrence of unfavorable socioeconomic 
characteristics,59 and biological immaturity.77
2.2 Parity 
Increased risk of fetal death in nulliparas (women with no previous births) is reported 
in several studies; case-control,78-80 hospital-based50 and population-based 
retrospective cohort studies23;59;60;66;68;81-85 (OR 1.2-1.9). Some of the risk may be 
explained by increased prevalence of hypertensive disorders (namely pre-eclampsia) 
and IUGR.60 Multiparity (>3 pervious births) has also been reported to increase the 
risk of fetal death (OR 1.7-2.9).23;50;59;70;80 and may partly be explained by selective 
fertility (replacement of a infant loss by new pregnancy).86
  
2.3 Maternal weight  
The proportion of overweight (25 kg/m2 > body mass index (BMI)<30 kg/m2) and 
obese (BMI >30 kg/m2) pregnant women is increasing in high-income countries. In 
the United States, reports from the National Health and Nutritional Survey estimated 
that 35% of women aged >20 years were obese in 2009-2010 (compared to 15% in 
1960).87;88 A large population-based cohort study in Norway during 2000-2007 
reported that approximately 30% of pregnant women (total cohort of 58 383) had a 
pre-pregnancy BMI >25 kg/m.89
The first study to report an increased risk of fetal death in women with high pre-
pregnancy BMI was a case-control study by Little and colleagues, using data from 
the 1980 United States National Natality and Fetal Mortality Survey.79 Even though 
the study only included married women, and had to rely on information collected by 
mail-in questionnaire, their results are in accordance with the results of several large 
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population-based prospective90-92 and retrospective cohort studies68;70;82;83;93-97 and 
two case-control study69;98 included in this review. All studies but one reported an 
increased risk of fetal death in overweight and obese women, however, varying BMI 
reference groups were applied and hence the results were not directly comparable. A 
dose-dependent relationship was proposed, as the risk of fetal death progressively 
increased with increasing BMI (overweight: OR 1.1-2.5 and obese: OR 1.4-3.2). The 
retrospective cohort study by Kashan and colleagues did not find any significant 
association between maternal BMI and stillbirth; however, the study missed 
information on BMI for a large proportion of the women (37%).99  
Weight gain during pregnancy was not associated with fetal death,92;98 whereas 
weight gain between pregnancies was reported to increase the risk.96;100 The 
Swedish study by Villamor and colleagues reported on changes in BMI between first 
and second pregnancies, and demonstrated that the risk of fetal death increased 
linearly with weight gain, and a weight gain of 3 BMI units increased the risk by 60% 
(OR 1.63, 95% CI 1.20-2.21).100 Overweight and obese women have a higher 
prevalence of hypertensive disorders, diabetes and, lower SES, but adjusting for 
these potential confounders did not change the risk estimates significantly.91;92;94;98
The association between low BMI/underweight has been less extensively studied, as 
most early studies applied women in the lowest BMI category as reference 
group.83;90;98 Studies assessing risk of fetal death in women with low BMI did not find 
any significant result.82;91;92;95;97
Two Danish studies reported causes of fetal death in overweight and obese women, 
and showed higher proportions of unexplained death (OR 3.6, 95% CI 1.8-7.6) and 
placental dysfunction (IUGR, placental infarctions and placental abruption) (OR 5.2, 
95% CI 2.5-10.9) in obese women compared to normal weight women.91;92  
Furthermore one study reported that the risk of fetal death in overweight and obese 
women was modified by gestational age.92 Nohr and colleagues noted that the 
increased risk of fetal death in overweight women at 37-40 weeks (hazard ratio (HR) 
1.7, 95% CI 0.9-3.0) compared to normal weight women, increased more as 
pregnancy advanced past 40 weeks (HR 2.9, 95% CI 1.1-7.7).92 However, a more 
recent study could not confirm the interaction between BMI and gestational age.97
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An association between maternal overweight and obesity and fetal death has clearly 
been made, however, the biological pathway remains unclear. The proposed 
mechanisms are: a) increased availability of nutrients causing expanded growth in 
the fetus, but inability of the placenta to supply oxygen to the fetus leading to hypoxia 
and death,91 b) hyperlipidemia resulting in lower levels of prostacycline and higher 
levels of thromboxane production increasing the risk of placental thrombosis,94 c) 
higher risk of congenital anomalies in the offspring and medical disorders as diabetes 
and hypertensive disorders in the mother,97 d) impaired ability to detect decreased 
fetal movements.97
2.4 Medical conditions  
Maternal medical conditions associated with fetal death are presented in Table 2. In 
the following section, the most prevalent disorders in pregnant women are further 
discussed: a) hypertensive disorders and b) diabetes. 
The prevalence of hypertensive disorders in the pregnant women varies across 
studies (depending on data source and population characteristics),55;101-106 Studies 
on hypertensive disorders and fetal death were very heterogeneous and therefore 
not easily comparable as different fetal death definitions( 20-28 weeks) and reference 
groups (normotensive women, low-risk pregnancies) were applied. 
Hypertensive disorders in pregnancy are associated with increased risk of fetal 
death, most consistently demonstrated for chronic hypertension with a two to three-
fold increase in risk.53;55;66;68;101;105;107-112 The Australian study by Heard and 
colleagues did not report significant increased risk of stillbirth among women with 
chronic hypertension relative to normotensive women during 1998-2001, however, 
the risk was significantly elevated in an earlier time period 1991-1997 (RR 3.4).103
Increased risk of fetal death is also reported among women with preeclampsia and 
pregnancy induced hypertension,55;66;101;102;105;113-116 however, in the most recent 
studies low risk and even lack of risk is reported possibly due to closer monitoring 
and timely delivery of the compromised fetuses.22;102;103;110;114;117 Gestational 
hypertension is categorized with preeclampsia in most studies from the United States 
(as pregnancy induced hypertension), however, when separately studied it was not 
associated with any increased risk of fetal death.103;104;117
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The risk of fetal death in women with hypertension is modified by gestational age. 
The risk of fetal death among women with chronic hypertension is increased but 
stable between week 36-38 and increases steadily thereafter.108 Among women with 
preeclampsia higher risk of fetal death was reported in early preeclampsia compared 
to late preeclampsia.115 The exact mechanism linking fetal death and hypertension is 
not clear, however, women with hypertension are more likely to give birth to low birth 
weight infants,101;103;104 most likely due to reduced uteroplacental blood flow.118   
Pregnancy in women with diabetes is associated with an increased risk of fetal death, 
and the incidence of this disorder is increasing.55;68;119;120  
Studies included in the review reported a 3 to 4-fold increased risk of fetal death in 
women with diabetes type 1,119;121-127 and a 2 to 3-fold increased risk among women 
with diabetes type 2 or pregestational diabetes,53;55;68-70;111;120;128-131 but higher risk in 
women requiring adjunctive insulin treatment.132;133
One of the largest studies on diabetes type 1 was a multi-center study conducted in 
Denmark in 1993-1999 (n=1218),127 identifying suboptimal glycemic control as the 
main contributing factor in this study. The increased risk among women with diabetes 
type 2 may pertain to higher prevalence of other risk factors as high maternal age, 
high BMI, ethnical diversity and social deprivation.124  
Factors contributing to the increased risk of fetal death in diabetic pregnancies are 
congenital anomalies (especially cardiac anomalies),121-124;127;129-131 pre-term 
births123;127;130 and fetal macrosomia.121;127;133 Diabetic women also have a three- to 
six-fold increased risk of hypertensive disorders.123;127;130  
Gestational diabetes is more prevalent than other types of diabetes; however, the 
association between this disorder and fetal death is uncertain. Two studies reported 
increased risk of fetal death,98;134 whereas three studies did not report any increased 
risk of fetal death,66;126;135 but reported higher risk of preeclampsia, caesarean 
section, macrosomia, preterm deliveres.135 Lack of an association between 
gestational diabetes and stillbirth may be due inability to diagnose all affected 
women, leading to high number of affected women in the control group resulting in 
attenuated estimates. Wood and colleagues conducted a nested case-control study 
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and reported higher stilllbirth rates in pre-diabetic women (who were later diagnosed 
with diabetes) compared to non-diabetic controls (OR 4.7).128 The authors suggested 
that the unexpected increased risk could be related to undiagnosed gestational 
diabetes or insulin resistance 
Several mechanisms have been proposed that may lead to fetal death in diabetic 
women: a) uncontrolled hyperglycemia and ketoacidoses,122 b) utero-placental 
impairment caused by microangiopathy, in particular among women with long 
duration type 1 or type 2 diabetes,133 c) fetal hyperglycemia leading to 
hyperinsulinemia, which further increases anaerobic metabolism and eventually 
hypoxia and acidosis.136
Table 2. Prevalence of maternal medical conditions associated with fetal 
death.10;32;101;103-105;112;113;121-124;127-133;137-141  
  Prevalence  
Fetal mortality rate (per 
1000 births) 
Hypertensive disorders 3.7-10%   
Preeclampsia 1.1-4.2% 7-26 
Gestational hypertension 2.1-4.3% 4-6 
Chronic hypertension 0.5-2.1% 8-16 
Diabetes  2.5-12%   
Type 1 or type 2 diabetes  0.5-2% 10-34 
Gestational diabetes 2-10% 5-10 
Thrombophilia 1-5% 18-40 
Renal disease <1% 15-200 
Systemic lupus erythematosus <1% 40-150 
Thyroid disease 0.2-2% 12-20 
Cholestasis of pregnancy <0.1% 12-30 
2.5 Smoking 
Maternal smoking is associated with an increased risk of fetal death (OR 1.2-2.0), 
and it has been argued that a causal relationship has been revealed.16;53;60;66;68-
70;79;83;142-148 There is a linear relationship between increasing risk of fetal death and 
increasing quantity of tobacco used.79;83;142;143;145 Pregnant women that quit smoking 
prior to 16 weeks of gestation have the same risk of fetal death as non-smokers.143
Women, who smoked during their first pregnancy, but not their second pregnancy, 
have the same risk in the second pregnancy as non-smokers.142 Maternal tobacco 
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exposure in utero is not associated with increased risk of stillbirth in the daughters of 
mothers that smoked during pregnancy.149  
The retrospective cohort study by Gray and colleagues reported that 38% of the 
inequality in stillbirth occurrence in Scotland could be attributed to smoking.147  A 
population-based retrospective cohort study (n=638,242) from Sweden reported an 
increased risk of stillbirth among smokers compared to non-smokers (OR 1.4, 95% 
CI 1.3-1.6), and demonstrated that after controlling for IUGR and placental 
complications (placental abruption, placenta previa and antepartum hemorrhage) the 
risk was no longer increased (RR 1.0, 95% CI 0.9-1.1).60 This finding supports the 
proposed mechanism involved in fetal death associated with smoking: a) smoking 
causes diffusion of nicotine and carbon monoxide across the placenta which inhibits 
fetal oxygen transport and increases vascular resistance, b) the placenta of smokers 
exhibits characteristic pathological features (decidual necrosis and infarcts), which 
are likely caused by smoking.  
Even though the rate of daily smokers among the pregnant population in Norway has 
declined (from 34% in 1987 to 11% in 2004 and 9.5% in 2012) the numbers are still 
quite high.1;150;151  
2.6 Alcohol and coffee consumption 
There are few studies of the association between alcohol consumption and the risk of 
fetal death.68;79;152-157 Two case-control studies have been conducted in the United 
States, one did not report any increased risk of fetal death among women reporting 
alcohol consumption during pregnancy,79 whereas the other study reported that each 
additional drink per week increased the risk by 1%.152 The increased risk of fetal 
death among abstainers reported by Little and colleagues may be due to “healthy 
drinker  effect”, as women with previous adverse outcome may abstain from alcohol 
in later pregnancies.79 Two studies reported that the risk was only significantly 
increased at early gestation (<16 weeks and <28 weeks, respectively), with no 
significant risk in late pregnancy.156;157 Kesmodel and colleagues conducted a 
prospective cohort study (n=24,768 women), and reported an increased risk of 
stillbirth in women who consumed >5 drinks per week, compared to women 
consuming <1 drink per week (RR 3.0, 95% CI 1.4-6.4).153  
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The proposed mechanisms that may lead to fetal death in women with high alcohol 
consumption are: a) fetoplacental dysfunction, b) increased production of 
prostaglandins, c) hypoglycemia.153  
Coffee consumption during pregnancy has been associated with increased risk of 
fetal death, however, only when moderate to high amounts are consumed; >3 cups of 
coffee per day (RR 1.7, 95% CI 1.0-2.8),153 >5 cups of coffee per day (OR 1.4, 95% 
CI 1.0-1.8),79 >8 cups of coffee per day (OR 3.0, 95% CI 1.5-1.9).158 Bech and 
colleagues conducted a prospective cohort study in Denmark and reported an 
increased risk of fetal death at 20-27 weeks of gestation in women consuming >4 
cups of coffee per day, whereas the risk was not significantly increased at gestational 
age >28 weeks.159  
The proposed mechanisms that may lead to fetal death in women with high coffee 
consumption are: a) increased levels of catecholamines in the maternal circulation 
that may cause vasoconstriction, b) placental dysfunction.159  
   
2.7 Social disparity and race/ethnicity 
Pregnant women reporting low SES or belonging to a racial/ethnic minority face a 
nearly two-fold increased risk of fetal death.24;25;68-70;147;148;160-185 In modern urban 
settings, many risk factors often coexist (low SES, racial/ethnic minority, smoking, 
teenage pregnancies) making the contribution of each risk factor difficult to 
disentangle. Women with low SES are more often smokers, have a higher BMI, and 
are more often unmarried, but even after adjusting for these risk factors the risk of 
fetal death is increased compared to women with high SES,164;166;168 especially for 
antepartum fetal deaths.163;168 Stephansson and colleagues found that even after 
controlling for an extensive number of maternal and pregnancy-related risk factors 
(maternal age, height, BMI, smoking, country of birth, number of antenatal care visits, 
involuntary childlessness) and excluding pregnant women with medical conditions 
(diabetes, pre-eclampsia and eclampsia) the increased risk related to low SES 
remained.168  
Social inequality in stillbirth may be explained by an increased frequency of negative 
life events, low level of education and more emotional problems (stress, anxiety and 
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depression), whereas the contribution of health risk behaviors (smoking, obesity) is 
small.148;168 Educational inequality in stillbirth is reported by several studies, and 
appears to persist over time.170;171 In addition, social disparity is more strongly 
associated with specific causes of stillbirth (unexplained,25;172 SGA,25;172 diabetes25), 
and stillbirth at preterm gestation.25
Substantial racial and ethnical disparity in stillbirth risk has recently been reported by 
several studies in high-income countries.24;160;162;165;167;169;173;174;176-186 Most studies 
regarding race are from the United States, and report an increased risk of fetal death 
among Black women compared to White women (OR 1.6-3.1),24;160;162;165;176;177;181
and a higher incidence of IUGR and pre-term births.162;165;181 The risk of stillbirth 
among Black women is reported to be greatest at 20-23 weeks of gestation and at 41 
weeks compared to White women.24 A Canadian study reported highest risk at late 
gestation (>37 weeks) among Aboriginal Canadian compared to non-Aboriginal 
Canadian.186
Ethnical inequality in stillbirth has been reported by studies comparing outcome 
among native-born and immigrant populations throughout Europe.173;174;179;180;183-185
Populations studied are heterogeneous and reason for the observed disparity 
remains uncertain.  
Proposed mechanisms to explain inequality in stillbirth risk among minorities are low 
SES,177;183 higher prevalence of maternal diseases,185;186 teenage pregnancies, and 
late start of prenatal care,179 consanguinity and congenital anomalies.186 Other 
studies did not confirm these associations.174;179;180
Two Norwegian studies reported a higher risk for antepartum fetal death among 
ethnic Somali women (OR 2.5, 95% CI 1.7-3.7) and non-Western women (OR 2.2, 
95% CI 1.3-3.8), compared to women of Norwegian and Western origin, 
respectively.167;169 The author hypothesized that sub-optimal care (defined as failure 
to act on non-reassuring fetal status or incorrect assessment of labor progression) 
may be an important contributing factor.167 The racial/ethnic disparity in pregnancy 
outcome may also be due to cultural differences concerning nutrition, self-care and 
compliance with medical recommendations, miscommunication and reduced 
effectiveness or access to health care. 
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2.8 Intrauterine growth restriction 
IUGR, in most studies defined as SGA with weight below the 10th percentile for a 
specific gestational age, is associated with increased risk of fetal death.8;70;80;84;187-195
SGA is often used in studies to indicate IUGR although not all SGA fetuses are 
pathological small. The magnitude of the risk also depends on whether population-
based birth weight (based on birth weights of infants born at particular gestational 
ages including both normal and abnormal outcome), population-based intrauterine 
fetal weights (assessed by ultrasound) or customized birth weight percentiles have 
been employed (based on ultrasound assessed intrauterine weights adjusted for 
maternal height, weight, parity and ethnic group, with the purpose to differentiate 
between constitutional and pathological smallness).80;188;190;192  
Of thirteen reviewed studies, nine retrospective cohort studies70;84;187-189;191-193;195 and 
four case-control studies,8;80;190;194 all reported increased risk of fetal death among 
fetuses that were SGA, and with accelerated risk as pregnancy advances. In the 
case-control study by Frøen and colleagues, among 76 validated unexplained fetal 
deaths (antepartum deaths that had undergone thorough post-mortem investigations) 
52% were SGA (birth weight <10th percentile of standard adjusted for gestational 
age, maternal weight, height, ethnicity and parity, and sex of the baby).190 The 
authors concluded that IUGR is one of the strongest risk factors for fetal death 
particularly among smokers and overweight and obese women.  
Interestingly an interaction between IUGR and certain risk factors such smoking and 
hypertensive disorders have recently been demonstrated. Gardosi and colleagues 
demonstrated that women in West Midlands who smoked during pregnancy but did 
not have a growth restricted fetus had the same risk of fetal death as non-smokers, 
whereas the risk increased when the fetus was growth restricted, but the highest risk 
was observed in non-smokers with IUGR.70 Likewise Helgadottir and colleagues in 
Norway observed that women with hypertensive disorders in pregnancy did not have 
an increased risk of fetal death without IUGR, whereas the risk increased when the 
fetus was growth restricted, and was highest among normotensive women with 
IUGR.53 Gardosi and colleagues concluded that women without recognized risk 
factors such as smoking may be considered low risk and therefore are less likely to 
have IUGR detected antenatally. 
IUGR may be caused by maternal, placental, uterine or fetal causes; however, the 
majority of cases are associated with placental insufficiency.196  
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2.9 Gestational age 
Several studies have reported increased risk of fetal death as pregnancy continues 
past term.85;189;197-202 The fetal mortality rate increases two- to three-fold at 42 weeks 
(1.6-3.7 per 1000 ongoing pregnancies) compared to 40 weeks (0.3-1.1 per 1000 
ongoing pregnancies).85;189;197;199 Some of the reported variation in fetal mortality is 
likely caused by the different methods of estimating gestational age (last menstrual 
period (LMP), or ultrasound), the local policy regarding expectant management or 
routine induction of labor at 41 weeks, and the period studied. The presumed 
mechanism is placental insufficiency, and this is supported by histological 
examinations of post-term placentas that revealed calcifications, infarcts, perivillous 
fibrin deposits and arterial thrombosis.189
The most recent studies report comparative estimates of gestational-age-specific 
fetal and neonatal mortality in high- and low risk pregnancies in an effort to deliver 
data regarding the optimal time for delivery.201;202  
The association between stillbirth and certain risk factors such as maternal age >35 
years, BMI >25, SGA, educational attainment and race is modified by gestational 
age.23-25;60;85;92;105;189 Reddy and colleagues reported that the RR of fetal death at 41 
weeks was 300% higher in women >40 years of age (RR 3.13, 95% CI 2.02-4.85) 
compared to women <35 years, whereas it was 85% higher at gestational age 39-40 
weeks (RR 1.85, 95% CI 1.43-2.39).23  
2.10 Previous stillbirth 
Increased risk of recurrent fetal death among women with a previous fetal death has 
been reported in two case-control studies (OR 10.2 and HR 5.8),203;204 and two 
population-based cohort studies.205;206 Samueloff and colleagues reported higher 
incidence of diabetes, hypertensive disorders and low birth weight infants among 
women with recurrent fetal death.203 Other previous adverse outcomes of the first 
pregnancy, such as preterm birth, giving birth to a SGA infant and developing pre-
eclampsia has also been associated with increased risk of fetal death in the 
subsequent pregnancy.207-210
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3. CAUSES AND CONSEQUENCES OF STILLBIRTH 
Causes 
Several classification systems of perinatal death have been developed since the 
Aberdeen classification was developed by Baird and colleagues in 1954.211 They 
developed the system after thorough examinations of 1008 perinatal deaths 
occurring during 1938-1952. The Aberdeen classification system identifies maternal 
and obstetrical clinical conditions that initiated the event leading to fetal demise. In 
1986 the extended Wigglesworth system was published, which implemented the 
pathophysiological processes leading to fetal death.212 These two systems are the 
most widely used, but they have a high number of unexplained deaths.213 Moreover, 
placental causes of death are not included. More than 30 classification systems have 
been developed; however, the ReCoDe system and the Tulip system are reported to 
perform better than other systems.36
Several studies have been conducted aiming to establish the cause of fetal death, 
but the proportion of unexplained deaths in these studies varied greatly, both due to 
the classification system applied and the intensity of investigations performed after 
stillbirth.12-14;16;17  
  
Fetal conditions
In high-income countries approximately 5-10% of fetal deaths are caused by fetal 
conditions, namely congenital anomalies (chromosomal anomalies and congenital 
malformations).17;19;214 Data from the Wisconsin Stillbirth Service Program reported 
that the most common disorders associated with fetal death are malformation 
syndromes and single malformations.215 In Canada, Liu and colleagues reported a 
declining fetal mortality rate due to congenital anomalies at term, presumably a result 
of the implementation of ultrasound screening (and other prenatal diagnostic tools) in 
antenatal care and selective termination of affected pregnancies.216
Infections
Maternal bacterial or viral infections during pregnancy have been reported to account 
for approximately 12% of fetal deaths in high-income countries.14 The 
microorganisms most frequently isolated in fetal death are group B streptococcus, 
Escherichia coli and Enterococcus fecalis.217 However the mere presence of 
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microorganisms does not prove causality, as chorioamnionitis or isolation of bacteria 
from the placenta is a common finding not only in cases of fetal death, but also in 
healthy controls.  
Some perinatal viral and protozoan infections have been associated with fetal death 
including human parvovirus B19 (PVB), cytomegalovirus, enterovirus, rubella, 
varicella zoster and Toxoplasmosa gondii (T. gondii).217 The majority of studies on 
viral infection and fetal death concern PVB, but show inconsistent results.218-224  
Three Swedish hospital-based studies carried out in 1992-1999 reported that 
between 7% and 15% of fetal deaths were PVB DNA-positive in fetal or placental 
tissue, compared to non PVB DNA-positive placentas among live born 
controls.220;223;224 However in these studies only a few cases had concomitant 
positive fetal and placenta specimens, and the use of placentas from live births as 
controls have been questioned. Hence the association of maternal PVB infection with 
fetal death needs to be further explored.   
The proposed mechanisms that may lead to fetal death in women with any type of 
infection are: a) high maternal fever, b) infection of the placenta causing impaired 
placental function, c) chronic fetal infection, which may lead to congenital anomalies, 
organ damage and pneumonia, d) infections promoting pre-term labor, increasing the 
risk of fetal death (in the very premature fetus).217
Umbilical cord abnormalities and cord accidents
Umbilical cord abnormalities and cord accidents such as cord prolapse, nuchal cord 
and true knots may cause fetal death.13;14
Placental pathology
Placental pathology is involved in more than 25% of fetal deaths.14 A comprehensive 
Dutch prospective cohort study of 750 intrauterine fetal deaths (>20 weeks of 
gestation) during 2000-2006, reported placental pathology as the main cause of fetal 
death.225 They reported that the pathology involved differed according to gestational 
age: fetal death <32 weeks involved placental bed pathology (i.e. spiral artery 
pathology or inadequate spiral artery remodelling causing placental abruption and 
infarction), whereas for fetal deaths >32 weeks of gestation, placental developmental 
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pathology (i.e. morphologic abnormalities due to abnormal development, causing 
placental hypoplasia and villus immaturity) dominated.   
Fetal maternal haemorrhage may cause fetal death if there is sufficient blood loss, 
leading to cardiovascular collapse.  
Prematurity/immaturity
Preterm premature rupture of membranes, preterm labor and cervical incompetence 
may cause intrapartum death in the immature fetus.13  
Consequences
Women who have given birth to a stillborn infant in the past more often report 
symptoms of anxiety than do women with live-born infants.226 A case-control study 
from the United Kingdom reported an increased risk of depression, post-traumatic 
stress disorder and anxiety in the subsequent pregnancy of women with previous 
fetal death (>18 weeks gestation) compared to women with one previous live birth.227
The authors conducted a 7-year follow-up study to assess the long-term 
psychosocial sequelae among these women. They reported no difference between 
cases and controls with respect to depression and post-traumatic stress disorder. 
However, the subgroup of women who reported symptoms of post-traumatic stress 
disorder 7 years earlier reported significantly higher levels of symptoms in the follow-
up study.228
A population-based cohort study conducted by Calderon-Margalitt and colleagues 
reported higher premature mortality in women with one prior fetal death (>28 weeks) 
compared to women with only live births (HR 1.40, 95% CI 1.11-1.77), even after 
adjusting for age, SES, parity, medical conditions at cohort enrolment and placental 
syndrome.229 Women with prior fetal death were at increased risk of death from 
coronary heart disease, circulatory or renal disorders. However, this association may 
have been confounded by pre-pregnancy BMI. A recent Danish study by Ranthe and 
colleagues with >15,000,000 person-years of follow up reported increased incidence 
of myocardial infarction, cerebral infarction and renovascular hypertension in women 
with prior stillbirth.230 It has been proposed that previous fetal death can be utilized as 
a sex-specific predictor of future cardiovascular disease.231
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4. CONCERNS AND GAPS RELATED TO STUDIES OF STILLBIRTH 
The literature review revealed several risk factors associated with fetal death. The 
association between maternal age and fetal death has been most frequently 
explored, and all studies reported an increased risk of fetal death among women 
aged >40 years,23;50-70 and all but three reported an increased risk among women 
>35 years,53;69;70 whereas six54;58;67;72-74 studies reported increased risk associated 
with young maternal age and three55;75;76 reported no risk. The studies applied 
different definitions of stillbirth and different reference groups. The effect of maternal 
age on the risk of stillbirth remains an object of concern, and further research is 
needed to elucidate the causal mechanisms involved.  
Primiparity was associated with fetal death,23;50;59;60;66;68;70;79-81;83-85 whereas six 
studies reported increased risk of fetal death in multiparous women.50;59;70;78;80;81  
Obesity was associated with increased risk of fetal death in all the reviewed papers 
but one, whereas five studies also reported an increased risk among overweight 
women.68-70;79;82;83;90-100 Four of these five studies utilized >15 years old data,79;83;94;98
hence, lack of an association between fetal death and maternal overweight in the 
majority of studies in this review, may be due to increased surveillance and 
interventions among these women.  
Increased risk of stillbirth in women with pregestaional diabetes was reported by 22 
studies,53;55;66;68-70;98;111;119-133 seven studies reported on diabetes type 1,119;121-125;127
and two studies reported on diabetes type 2.124;129 Gestational diabetes was 
associated with increased risk of fetal death in two studies,98;134 whereas three did 
not report an increased risk.66;126;135 Chronic hypertension was reported to increase 
the risk of fetal death in 15 studies.53;55;66;68;101;104;105;107-113;117 One Australian study 
did not report increased risk of fetal death among women with chronic hypertension, 
103 however, the authors reported a significantly higher elective Caesarean rate in 
these women compared to normotensive women and women with pregnancy 
hypertension. Preeclampsia was associated with increased risk in four 
studies,66;102;114;115 and no risk in three studies.104;110;117  
Sixteen studies reported an increased risk of fetal death among smokers and the 
result was very consistent.16;53;60;66;68-70;79;84;142-148 Studies on alcohol consumption 
during pregnancy and risk of fetal death were few and very heterogeneous; one 
study reported increased risk among abstainers, whereas the majority of studies 
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reported increased risk associated with alcohol consumption.68;79;152-157 However, two 
studies reported that the risk was only significantly increased at early gestation (<16 
weeks and <28 weeks, respectively).156;157 Moderate to high amounts of coffee 
consumption was associated with increased risk of fetal death in 4 studies.79;153;158;232  
Low SES measured by educational attainment, household income or employment, 
was associated with an increased risk of stillbirth.25;147;148;163;164;166;168;170-172 Likewise, 
a consistent strong association between fetal death and ethnic minority status or 
being Black was reported by large number of studies (24 papers).24;68-70;160-
162;165;167;169;173-186 Understanding why disadvantaged women have a poorer 
pregnancy outcome and how to create prenatal care that is better targeted to this 
group is required.  
IUGR assessed by the proxy SGA was associated with increased risk of fetal death 
in 13 studies.8;70;80;84;187-195 A better understanding and ability to identify true 
pathological growth is warranted. In addition an optimal timing for the delivery of 
cases with pathological growth needs to be estimated.  
Post term pregnancy is associated with increased risk of stillbirth.85;189;197-202 In high-
risk pregnancies, in which diabetes, pre-eclampsia or severe SGA are a factor, labor 
is routinely induced near term. However, there is continuing controversy about the 
appropriate management of low-risk singleton pregnancies past term.  
Women with a previous stillbirth have an increased risk of recurrence,203-210 and 
previous stillbirth was claimed to be the strongest pre-pregnancy risk factor in one 
study.69  
Stillbirth is the endpoint of numerous pathways, and different risk factors are 
associated with different causes. In Figure 4, a conceptual model of risk factors 
associated with fetal death from the literature review is depicted. Risk factors may be 
both directly and indirectly associated with stillbirth, for example high maternal age, 
which is directly associated with stillbirth but also indirectly associated through the 
increased risk of medical conditions or high BMI. The figure further depicts the link 
between sociodemographic, behavioral and pregnancy-related risk factors and more 
proximate factors in the causal pathway to fetal death (congenital anomalies, 
placental disorders, infections and preterm labor). However, the Figure is not 
exhaustive.     
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Figure 4. A conceptual model illustrating causes and risk factors associated with fetal death.
During the last century fetal mortality rates in most high-income countries have 
declined.233 However, there is still significant inter- and intra-country inequality in 
stillbirth.44;45;234 To address these differences and achieve further reductions it is 
imperative that the specific causes of, and risk factors for fetal death are identified, 
and predictive models established. Even though several risk factors have been 
identified, understanding and prevention is hampered by limitations and gaps in the 
knowledge on fetal death.70 The only antenatal screening method in recent time, that 
has been shown to reduce risk of stillbirth is the use of fetal umbilical Doppler blood 
flow measurements in high-risk pregnancies.235;236
Epidemiological research on fetal death is conducted using observational studies, 
which harbor the inherent risk of finding an association due to chance or bias. 
However, the probability of finding a “true” association increases when observations 
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are repeated in different populations with consistent results, and at the same time are 
plausible and exhibit a biological gradient. Furthermore, it has been indicated that 
real-life observational studies of mortality trends may provide strong reality-based 
evidence, in particular when studying fetal mortality in obstetrics as non-
interventional studies are not feasible due to ethical considerations.237  
Cohort studies of outcomes that are as rare as fetal death require large datasets. 
Hence most research to-date has taken the form of retrospective studies utilizing vital 
statistics from registries data that often lack detailed information on confounders. 
Several large population-based cohort studies conducted in the United States 
obtained data on fetal death from the Centers for Disease Control and Prevention’s 
National Center for Health Statistics, which receives standard reports of fetal death 
from the independent reporting areas (states and territories). However, reporting 
requirements and criteria vary between the reporting areas, and fetal death reports 
are flawed by underreporting, missing data and low accuracy.238;239        
We were able to study fetal death in Norway by utilizing data from the MBRN. This 
registry, like the other Nordic medical birth registries, is a valuable resource for 
population-based data that has been prospectively collected in a standardized 
manner with nearly 100% coverage of all births in Norway.6 The use of MBRN data 
eliminates selection bias due to non-response. Longitudinal monitoring over time 
enables the study of trends to elucidate changes in disease/mortality patterns in the 
population, and at the same time facilitates the evaluation of healthcare services 
delivered. However, as will be elaborated upon later, the use of secondary data (data 
generated for a different purpose) has certain drawbacks, such as inaccuracy in the 
measurement of exposure and outcome, and limited data on confounders.240
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5. AIMS OF THE THESIS 
The main aim of this thesis was to study trends of fetal death and associated factors 
in Norway. 
It has been reported that infection is an important cause of stillbirth, specifically in 
early fetal deaths (<28 weeks of gestation).22;217 Hence, studies of late fetal death 
(>28 weeks) may underestimate the impact of infection. Moreover, knowledge on 
viral causes of fetal death is limited due to complex detection techniques, so studies 
in high-income countries differ in the reported rate of infection as a cause of fetal 
death, due to different study designs and the degree to which investigations were 
performed, with higher numbers reported in prospective studies with extensive 
investigation protocols (culture, serology, histology, molecular biology 
techniques).17;241  
PVB has been reported to be an important cause of fetal death throughout gestation, 
however, studies on PVB and fetal death are not consistent. Hence we aimed to 
study the association between PVB and fetal death in a large population-based study 
in Norway in Paper I. 
In Norway, there have been large changes in the management of pregnant women, 
especially since the 1980s, with the introduction of ultrasound, cardiotocography, 
increasing numbers of caesarean sections and inductions of labor performed. We 
wanted to study trends in fetal death at different gestational ages in Paper II. 
Moreover, in this thesis we wanted to estimate the impact of certain risk factors 
reported to be associated with fetal death, such as high maternal age in Paper III, 
and hypertensive disorders in Paper IV. There is a lack of knowledge on gestational-
age-specific risk of fetal death in high-risk pregnancies, and therefore this was further 
explored in this thesis.  
More specifically we aimed to: 
1. Study the association between past and present maternal human PVB 
infection and fetal death, birth weight and length of gestation. 
2. To study trends in fetal mortality at different gestational ages in Norway in 
1967-2006.  
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3. To study changes in the association of fetal death with maternal age at 
different gestational ages. 
4. To study changes in the association of fetal death with maternal hypertensive 
disorders (pre-eclampsia, gestational hypertension and chronic hypertension).  
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6. MATERIALS AND METHODS 
6.1 Toxoplasmosis Study (Paper I) 
In the first study we used data from the Toxoplasmosis Study. This nationwide 
prospective study was conducted by the Norwegian Institute of Public Health from 
June 1992 to May 1994, and included approximately 60% of all pregnant women in 
Norway during this period (n=35 940 pregnant women).242 It was primarily designed 
to study risk factors, prevalence, incidence and vertical transmission rate of T. gondii
among pregnant women.   
Women were invited to participate in the study at their first antenatal visit to the 
primary healthcare center (mean gestational age 10.2 weeks) where the first of three 
serum samples was requested. Retesting was requested for the women without 
antibodies against T. gondii at 22 and 38 weeks of gestation (76.3% women provided 
all three serum samples). If any sample indicated possible primary infection an 
additional sample was requested for confirmation. An additional serum sample was 
also requested in the case of fetal death or miscarriage.  
6.1.1 Study design and population  
A linkage between the Toxoplasmosis Study Registry and the MBRN was performed 
by personal identification numbers so as to identify women with live-born (n=957 
controls) and stillborn (>16 weeks of gestation) (n=281 cases) infants (Figure 5). 
Based on this a case-control study was conducted.  
6.1.2 Blood sampling and analysis 
The blood samples were collected during June 1992 to May 1994 and stored at  
–20°C at the Norwegian Institute of Public Health. The sera were analyzed for PVB 
antibodies during 1996. The first serum sample from each woman was tested 
separately for immunoglobulin G (IgG) and immunoglobulin M (IgM) antibodies 
against PVB (IDEIA, DAKO A/S, Copenhagen, Denmark). If the first serum sample 
was negative the last available serum sample from the woman was analyzed to 
detect seroconversion. Serum that tested positive within the grey zone was retested. 
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Toxoplasmosis Study participants: 
N=35,940
Personal identification 
number missing: N=1,851 
Linkage with MBRN:                       
N=34,089
Fetal death >16 weeks: 
N=283
Insufficient serum 
available: N=2
Cases
N=281
Random group of live 
births:  N=970
Controls
N=957
Insufficient serum 
available: N=13
Figure 5. Study population for Paper I.
6.1.3 Variables 
Main outcome variable 
Fetal death was defined as death >16 weeks of gestation as notified to the MBRN. 
No distinction was made between antepartum and intrapartum deaths.  
Secondary outcome variables 
Birth weight information on birth weight (g) was obtained from the MBRN. Previous 
studies have reported higher than expected proportion of small for gestational age 
infants among serologically confirmed maternal PVB infection.218
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Gestational age (weeks) was obtained from the MBRN. Perinatal infections generally 
have been associated with preterm delivery.217
Explanatory variables 
Maternal PVB antibody status was categorized in the following manner: 
1. Antibodies against PVB not detected: no past or present infection.
2. Presence of IgG antibodies against PVB in the first serum sample (but no IgM 
antibodies): previous infection.
3. Presence of IgM antibodies against PVB in the first serum sample: acute infection.
4. Seroconversion (occurrence of IgG or IgM antibodies in seronegative women): 
acute infection. 
Maternal age at delivery was categorized as (<30 or >30 years). Previous studies 
have reported increased risk of fetal death at both extremes of maternal age,58 and 
seroprevalence of IgG increases with age.243
Parity was defined as the number of previous births (after >16 weeks of gestation) 
and was categorized as 0,1 and >2. High parity is associated with increased risk of 
fetal death, and increased risk of acquiring PVB infection.244  
6.1.4 Statistical analysis 
The association (ORs with 95% CIs) between maternal PVB antibody status 
(exposure) and fetal death (outcome) was estimated by contingency tables. 
Hypothesis testing was performed by chi-squared test (Ȥ2), and by Fishers exact test 
when the expected frequencies were less than 5. Multivariate logistic regression 
models were applied to assess the relationship between exposure and outcome 
allowing for adjustment for the confounding effect of maternal age and parity. Among 
women followed with regard to seroconversion additional adjustment for follow-up 
time was made.  
Differences in mean birthweight and length of gestation among cases and among 
controls according to maternal PVB antibody status were tested by the Student t-test. 
Among cases with presence or absence of IgM antibodies or occurrence of IgG or 
IgM antibodies, the Mann-Whitney test (non-parametric) was applied due to small 
numbers and non-normally distributed outcomes as this test is more robust to 
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outliers. All statistical analyses were performed using the Statistical Package for the 
Social Sciences (SPSS, version 15.0; SPSS Inc., Chicago, Illinois, USA). 
6.1.5 Ethical aspects 
The study was approved by the Norwegian Data Inspectorate, the National Board of 
Health, the Regional Ethical Committee for Medical Research and the Advisory 
Committee for the MBRN. 
6.2 The Medical Birth Registry of Norway (Papers II-IV) 
In the Papers II-IV we used data from the MBRN, which was established in 1967 with 
the following purpose: 
“to perform epidemiological surveillance of birth defects and other perinatal health 
problems in order to detect increases in rates.”6
It is mandatory to report all births (live births and fetal deaths) >16 weeks of gestation 
(since 1999, 12 weeks of gestation) to the registry. A standardized notification form is 
filled in after the delivery by the attending midwife or physician within 7 days of 
delivery. The form contains information on maternal health (before and during 
pregnancy) and outcome of the pregnancy (maternal and neonatal). The form went 
unchanged from 1967-1998, but as from 1999 a new form was implemented. The 
main changes in the new form were the inclusion of information regarding maternal 
smoking habits, use of nutritional supplements, and the former text regarding 
maternal health was replaced by pre-coded fields for maternal disorders. Before 
1988 terminated pregnancies were only infrequently notified to MBRN, and from 
1988 to 1998 terminations due to serious congenital anomalies were notified as 
stillbirths. In 1999 a separate register for pregnancy terminations after 12 weeks of 
gestation was established within the MBRN. Complete case ascertainment (births 
and deaths) is maintained in the registry due to routinely executed record linkage 
with the Cause of Death Registry and the National Population Registry.  
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6.2.1 Study design and population 
In the Papers II-IV we conducted population-based retrospective cohort studies. For 
details about the population and exclusion criteria see Figure 6. The inclusion and 
exclusion criteria were the same in Papers II-III whereas in Paper IV we included only 
pregnancies >20 weeks and excluded multiple pregnancies.  
Medical Birth Registry of Norway 1967-2006
Births: N=2,337,775
Missing length of gestation 
N=125,997 
Length of gestation >16 
weeks Births: N=2,337,392
Length of gestation >20 
weeks Births: 2,333,450
Missing length of gestation 
Births: N=125,997 
Length of gestation >43 
weeks N=28,595
Missing maternal age 
N=40
Multiple pregnancies 
N=60,498
Missing parity N=13
Study population Paper IV 
2,121,371
Length of gestation >43 
weeks N=28,595
Missing maternal age 
N=40
Missing parity N=13
Study population Paper II and III
2,182,756
Figure 6. Study population for Papers II-IV.
58
6.2.2 Variables 
Main outcome variables 
Paper II 
Fetal death was defined as death at >16 weeks of gestation as notified to the birth 
registry. We studied fetal death at different equal lengths of gestation: 16+0-22+6, 
23+0-29+6, 30+0-36+6 and 37+0-43+6 weeks (the superscripts denote days in addition to 
completed weeks).  
Perinatal mortality was defined as the sum of fetal death at 22 weeks of gestation 
and infant death within 7 days of birth. 
Early neonatal mortality was defined as the number of infant deaths within 7 days of 
birth. 
Stillbirth (Paper II) was defined as fetal death >22 weeks of gestation. 
Paper III 
Fetal death was defined as death at >16 weeks of gestation as notified to the birth 
registry. We studied fetal death at different equal lengths of gestation: 16+0-22+6, 
23+0-29+6, 30+0-36+6 and 37+0-43+6 weeks. We also studied fetal death at: 38+0-39+6, 
40+0-41+6, and 42+0-43+6 weeks of gestation. 
Paper IV 
Fetal death was defined as death at >20 weeks of gestation. We studied risk of fetal 
death at the following equal lengths of gestation: 20+0-23+6, 24+0-27+6, 28+0-31+6, 32+0-
35+6, 36+0-39+6 and 40+0-43+6 weeks.  
Perinatal mortality was defined as the sum of fetal death at 22 weeks of gestation 
and infant death within 7 days of birth. 
Explanatory variables 
Paper II 
Period of delivery (year) or year of birth as reported to the MBRN was the main 
explanatory variable, and was categorized as: 1967-1971, 1972-1976, 1977-1981, 
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1982-1986, 1987-1991, 1992-1996, 1997-2001 and 2002-2006. In the analysis the 
years 1967-1971 was used as reference to study trends in fetal death. 
Maternal age at delivery was categorized as <20, 20-24, 25-29, 30-34, 35-39, 40-44, 
and >45 years. Previous studies have reported increased risk of fetal death at both 
extremes of maternal age,23;58 and maternal age at delivery has increased in recent 
years.1
Parity was defined as the number of previous births (after >16 weeks of gestation) 
and was categorized as 0,1,2,3 and >4. Primiparity and also grand multiparity may 
increase the risk of fetal death.60;78  
Plurality was coded as either a single infant or two infants or more. Multiple 
pregnancies confer an increased risk of fetal death,36 and the number of multiple 
pregnancies has also increased in the last 40 years.1  
Paternal age was categorized as <30, 30-39, >40 years and missing (1%). High 
paternal age is associated with increased risk of fetal death.245 Paternal age is 
correlated with maternal age, and as maternal age has increased, paternal age may 
also have changed. 
Pre-eclampsia was defined as an increase in blood pressure to at least 140/90 
mmHg combined with proteinuria after completed 20 weeks of gestation (1967-1998: 
ICD-8 codes 637.4 / 637.5 / 637.6 / 637.9 and 1999-2006: ICD-10 codes O13 and 
O14). Preeclampsia is associated with fetal death102 and increased prevalence in 
Norway since 1967 has been reported.246   
Paper III 
Maternal age at delivery was the main explanatory variable and was categorized as 
<20, 20-24 (reference), 25-29, 30-34, 35-39, 40-44, and >45 years. The last two 
categories (40-44 and >45 years) were merged due to insufficient numbers in certain 
analyses.  
Period of delivery (year) was categorized as: 1967-1971, 1972-1976, 1977-1981, 
1982-1986, 1987-1991, 1992-1996, 1997-2001 and 2002-2006. 
Parity was defined as the number of previous births (after >16 weeks of gestation) 
and was categorized as 0,1,2,3 and >4. Primiparity and also grand multiparity may 
increase the risk of fetal death and is associated with maternal age.60;78
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Plurality was coded as either a single infant or two infants or more. Multiple 
pregnancies confer an increased risk of fetal death36 and are associated with high 
maternal age.247
Paternal age was categorized as <30, 30-39, >40 years and missing (1%). High 
paternal age is associated with increased risk of fetal death.245, and is correlated with 
maternal age. 
Pre-eclampsia was defined as an increase in blood pressure to at least 140/90 
mmHg combined with proteinuria after completed 20 weeks of gestation (1967-1998: 
ICD-8 codes 637.4 / 637.5 / 637.6 / 637.9 and 1999-2006: ICD-10 codes O13 and 
O14). Preeclampsia is associated with fetal death,102 and also associated with 
maternal age.56
Paper IV 
Pre-eclampsia, gestational hypertension and chronic hypertension were the main 
explanatory variables: 
Pre-eclampsia was defined as an increase in blood pressure to at least 140/90 
mmHg combined with proteinuria after completed 20 weeks of gestation (1967-1998: 
ICD-8 codes 637.4 / 637.5 / 637.6 / 637.9 and 1999-2006: ICD-10 codes O13 and 
O14). Eclampsia was defined as preeclampsia with seizures. Eclampsia and HELLP 
(Hemolysis, Elevated Liver Enzymes, and Low Platelets) were grouped together with 
pre-eclampsia. Women with chronic hypertension who developed preeclampsia 
during pregnancy were assigned to the preeclampsia group.  
Gestational hypertension was defined as an increase in blood pressure to 140/90 
mmHg after 20 weeks of gestation without concomitant proteinuria (1967-98: ICD-8 
codes 637.0/637.2 and 1999-2006 ICD-10 code O16).  
Chronic hypertension was defined as pre-pregnancy systolic blood pressure at 140 
mmHg or diastolic blood pressure at 90 mmHg, or an increase in blood pressure to 
these values before 20 weeks of gestation (1967-1998: ICD-8 codes 400-404 and 
1999-2006: ICD-10 codes I10/I11/I12/I13/I15/O10/O11).  
Maternal age at delivery was the main explanatory variable and was categorized as 
<19, 20-24, 25-29, 30-34, 35-39 and >40 years. Maternal age is associated with fetal 
death and older women have higher prevalence of hypertensive disorders.56
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Parity was defined as the number of previous births (after >16 weeks of gestation) 
and was categorized as 0,1,2,3 and >4. Primiparity and also grand multiparity may 
increase the risk of fetal death78 and primiparity is associated with pre-eclampsia.248
6.2.3 Data preparation
The source of data for the studies was raw data file from the MBRN. The file was 
examined and data converted trough several syntaxes. Fetal death was collapsed 
into one category, and then grouped according to gestational age at death. For the 
regression analyses continuous variables were categorized to be able to adjust for 
explanatory variables. 
    
6.2.4 Theoretical basis of the statistical analysis in Papers II-IV 
The concept of stillbirth risk has to be further elaborated. The overall stillbirth risk is 
straightforward calculated as the proportion of stillbirths among all births. However, 
gestational-age-specific risk of stillbirth is more complicated, but nevertheless 
important in the understanding and prevention of this outcome. There is an ongoing 
dispute on which epidemiologic method to apply when estimating gestational-age-
specific risk of stillbirth.249-253 The conventional definition is the number of stillbirths at 
a given gestational week divided by all births (live birth + stillbirths) at that gestational 
week:   
number of stillbirths(i) 
Stillbirth rate in week i=
total births(i)  
  
By applying the conventional definition, the fetal death risk is highest early in 
gestation, declines with advancing pregnancy duration, and then rises slightly at post 
term gestational age.249 This is claimed to be inconsistent with the observed changes 
in obstetric practice, where increasing rates of medically indicated iatrogenic preterm 
deliveries has coincided with declining stillbirth rates.251  
The second problem with the conventional definition regards the paradox of 
intersecting gestational-age-specific perinatal mortality curves.251 This phenomenon 
pertains to the observed difference in the gestational-age-specific perinatal mortality 
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rates for different risk factors such as smoking or race. For such factors the stillbirth 
rate curves are expected to intersect as gestation advances; with high risk women 
(smokers) having relatively lower risk of stillbirth in early gestation and relatively 
higher risk at late gestation compared to low risk women (non-smokers). The 
alternative definition proposed to circumvent these issues is by applying the “fetus-at-
risk” model.  
The “fetus-at-risk” model first proposed by Yudkin and colleagues21 has the following 
definition (numbers of stillbirths at a given week divided by number of total births at a 
given week of gestation or greater):     
  
number of stillbirths(i)   
Stillbirth rate in week i= total births(j>i) 
  
As not only fetuses delivered at a specific gestational week are at risk of fetal death 
but all ongoing pregnancies are included in the denominator. By applying the “fetus 
at risk” definition the fetal mortality rate is very small in early gestational age and 
increases exponential with gestation,249 hence, justifying early selective delivery for 
medical indications.251 Platt and colleagues further proposed that gestational age 
should be considered as the timescale in time to event analysis with “fetus’s-at-risk” 
as denominator. 254 The risk of stillbirth is then compared between different groups by 
Cox-regression analysis. 
Both models of estimating gestational-age-specific rate of fetal death are widely 
applied in the literature, and may answer different clinical questions.250 In Paper II 
and III we applied the “fetus-at-risk” model, whereas in Paper IV the conventional 
model was applied. 
6.2.5 Statistical analysis 
Papers II-III 
In Papers II-III Cox regression (or proportional hazards) models were applied to 
compare the rate of fetal death among the exposed and unexposed, and adjustment 
for confounding was made by including these variables as explanatory variables. 
These models were applied to estimate the hazard rate ratio (referred to as RR in the 
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Papers II and III) of fetal death according to period of delivery (Paper II) and maternal 
age (Paper III), as we had censored data with varying follow-up times. Event times 
(or “survival times as fetuses”) were gestational age until the study outcome (fetal 
death). Live births were treated as censored observations. Separate analyses were 
performed for the different gestational age intervals since the purpose of the studies 
was to investigate gestational specific differences. A fetus not born at the end of an 
interval was treated as a censored observation in that interval (irrespectively of the 
eventual outcome of pregnancy). 
Due to the fairly short gestational age intervals the results are not very sensitive to 
the proportional hazards assumption. To illustrate this I used a standard technique 
for validating the proportional hazards assumption, namely the log-minus-log plots. 
Assuming that the hazard ratio between the exposed and unexposed groups is 
constant, the log-minus-log plot of survival against gestational age should give 
parallel lines. The proportional hazards assumption was fairly good when stratified by 
short gestational length groups as illustrated by parallel lines in Figure 7, compared 
to complete pregnancy in Figure 8 where the curves crossed.  
Figure 7. Logminuslog plot for gestational weeks 30-36.*  
*(faarny: birth year group; svangerskapslengde i dager: gestational length in days)
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Figure 8. Logminuslog plot for gestational weeks 16-43.* 
*(faarny: birth year group; svangerskapslengde i dager: gestational length in days)
Perinatal mortality, early neonatal mortality and stillbirth rates were estimated per 
1000 births. The occurrence of fetal death at different gestational ages was estimated 
per 1000 ongoing pregnancies, and for the last gestational age group (37-43 weeks 
of gestation) a correction was made to more accurately estimate the incidence rate, 
by multiplying the denominator with a correction factor (0.5), as only fetus’s in utero 
are under risk of fetal death.   
Paper IV 
In Paper IV the models applied were different than those in Papers II-III, as presence 
of the time-dependent covariates pre-eclampsia and gestational hypertension were 
only registered at delivery. Therefore it was not possible to address the hazard rates 
of fetal death at different periods of pregnancy. It was, however, possible to estimate 
the probability of a fetal death given a birth at a specific time by applying the 
conventional model to estimate the gestational-age-specific stillbirth risk. Thus the 
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proportion of fetal death per 1000 births for the different hypertensive disorders in 
different time intervals of pregnancy were estimated. Furthermore, at each time 
interval regression models were applied to calculate (adjusted) RRs of fetal death 
given a birth.  
Instead of using a logistic regression model we estimated the associations between 
the different hypertensive disorders and fetal death by RRs by applying generalized 
linear models with a log-link to the binary outcome fetal death (yes/no). This model 
was applied in order to have an easy parameter interpretation. With this model one 
estimates risk ratios or the ratio of probabilities of fetal death among different groups 
adjusted for the confounder. When the outcome is rare the RR-estimates are 
approximately equal to the ORs, but for non-rare events such as the risk of fetal 
death early in the pregnancy, the interpretation of OR is not straightforward. 
Uncertainty of estimates was reported by 95% CIs.  
All statistical analyses were performed by using the SPSS, version 16.0 (SPSS Inc., 
Chicago, Illinois, USA). 
6.2.6 Ethical aspects 
The MBRN was approved by the Norwegian Data Inspectorate. The Publishing 
Committee of the MBRN approved our study. 
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7. MAIN RESULTS (summary of Papers I-IV) 
7.1 Paper I 
Maternal human parvovirus B19 infection and the risk of fetal death and low 
birth weight: a case-control study within 35 940 pregnant women. 
Aim: The aim of this study was to assess the association between maternal PVB 
infection and fetal death, birth weight and length of gestation.  
Method: We conducted a population-based case-control study in Norway. Cases 
(n=281) were all women who experienced fetal death within a cohort of 35 940 
pregnant women that participated in the Toxoplasmosis Study during 1992-1994, and 
the control group consisted of a random sample of 957 women with a live-born child. 
Information on pregnancy outcome was obtained from the MBRN. First trimester 
serum samples were tested for antibodies against PVB (IgM and IgG). In 
seronegative women, additional sera were analyzed to detect seroconversion during 
pregnancy. The association between parvovirus B19 infection and fetal death was 
estimated by contingency tables and logistic regression. The mean birth weight and 
length of gestation among cases and controls according to maternal antibody status 
was calculated and differences tested with the Student t-test and the Mann-Whitney 
test. 
Results: Two of the 281 (0.7%) women who experienced fetal death, and nine of the 
957 (0.9%) controls had IgM antibodies (crude OR 0.8, 95% CI 0.2-3.5). In women 
who were seronegative in the first trimester, 3.1% (2/65) with fetal death and 2.6% 
(8/307) with a live birth seroconverted (crude OR 1.2, 95% CI 0.2-5.7). Neither 
presence of maternal PVB-specific IgG or IgM antibodies in the first trimester, nor 
was seroconversion during pregnancy associated with lower birth weight or reduced 
length of gestation in live-born children, but it was associated with low birth weight in 
stillborn infants, however, this difference was not statistically significant (P=0.1). 
Conclusion: In this case-control study PBV infection was not significantly associated 
with risk of fetal death, and only four of the 281 women with fetal death were infected. 
However, the lack of association may also be due to sample size limitations. 
67
7.2 Paper II 
Changes in fetal death risk during 40 years - different trends for different 
gestational ages: a population-based study in Norway. 
Aim: The aim of this study was to study trends in perinatal mortality, early neonatal 
mortality and gestational-age-specific risk of fetal death during 1967-2006. 
Method: We conducted a register-based observational study of all pregnancies (>16 
weeks of gestation) during 40 years in Norway (n=2 182 756). Data was obtained 
from the MBRN. Changes in the absolute risks and hazard ratios (HR) of fetal death 
in ongoing pregnancies were estimated. Cox regression models were applied to 
estimate the HRs of fetal death according to period of delivery (1967-1971, as 
reference) in the following gestational weeks: 16-22, 23-29, 30-36 and 37-43. 
Adjustment for confounding was made by including these variables as explanatory 
variables in multivariable Cox regression models. 
Results: In all pregnancies lasting longer than 22 weeks, the fetal mortality rate 
decreased during 1967-2006. The greatest absolute decline was in term pregnancies 
(37-43 weeks) in which fetal mortality rates declined from 10.8 per 1000 ongoing in 
1967-1971to 3.3 in 2002-2006 (crude HR 0.35, 95% CI 0.31-0.38). In pregnancies at 
30-36 weeks the fetal mortality rate declined from 4.5 to 1.1 per 1000 (crude HR 
0.23, 95% CI 0.21-0.26). At 23-29 weeks, the rate declined from 2.8 to 1.3 per 1000 
(crude HR 0.46, 95% CI 0.40-0.52). An opposite trend was observed at early 
gestation (16-22 weeks) with an increase from 1.7 to 3.4 fetal deaths per 1000 
ongoing pregnancies (crude HR 2.05, 95% CI 1.84-2.27). Adjustments for maternal 
age, parity, multiple pregnancies, paternal age and pre-eclampsia did not significantly 
alter the estimated associations. 
Conclusion: Since 1967 the risk of fetal death has been reduced by almost 70% in 
pregnancies lasting longer than 22 weeks. However, at 16-22 weeks of gestation an 
increase in risk was observed. This increase may be artificial, perhaps caused by 
improved reporting routines of early fetal deaths. However, we speculate that some 
of this increase may be caused by an increased proportion of childbearing women 
being treated with cervical cone excision prior to pregnancy. 
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7.3 Paper III 
The impact of maternal age on fetal death: does length of gestation matter? 
Aim: Several studies have reported an increased risk of fetal death among older 
women. The aim of this paper was to study the association between fetal death and 
maternal age by length of gestation in Norway. 
Method: We conducted a population-based observational study including all ongoing 
pregnancies >16 weeks of gestation in Norway in 1967-2006 (n=2 182 756). Data 
was obtained from the MBRN. Changes in the absolute risks and HRs of fetal death 
in ongoing pregnancies were estimated. Cox regression models were applied to 
estimate the HR of fetal death according to maternal age at delivery categorized as 
less than 20, 20-24 (reference), 25-29, 30-34, 35-39, 40-44, and 45 years and older 
in the following gestational weeks: 16-22, 23-29, 30-36 and 37-43. Adjustment for 
confounding was made by including these variables as explanatory variables in 
multivariable Cox regression models. 
Results: The risk of fetal death was 1.4 times higher in women 40-44 years old than 
in women aged 20-24 in mid-pregnancy (crude HR 1.43, 95% CI 1.18-1.74), but 2.8 
times higher at term (crude HR 2.8, 95% CI 2.43-3.23). In term pregnancies the 
relative importance of maternal age increased with each additional week of 
pregnancy. In gestational weeks 42-43, the crude risk was 5.1 times higher in 
mothers 40 years (crude HR 5.09, 95% CI 3.55-7.31). In the more recent period 
(1987-2006), the elevated risk of fetal death in elderly mothers at term was 
attenuated.  
Conclusions: Women >40 years had the highest risk of fetal death throughout 
pregnancy, particularly in term and post-term pregnancies. Improved obstetric care 
may explain the attenuation of risk of fetal death (>40 weeks of gestation) associated 
with age in recent time. 
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7.4 Paper IV 
Hypertensive disorders in pregnancy and fetal death at different gestational 
lengths: a population-based study of 2,121,371 pregnancies. 
Aim: The aim of this paper was to compare the proportion of stillborn infants in 
pregnancies with pre-eclampsia, gestational hypertension or chronic hypertension 
with normotensive pregnancies. 
Method: We conducted a register based observational study including all singleton 
births >20 completed weeks of gestation in Norway in 1967-2006 (n= 2 121 371). 
Data was obtained from the MBRN. The proportion of fetal death per 1000 births was 
estimated in normotensive pregnancies, and in pregnancies with pre-eclampsia, 
gestational hypertension and chronic hypertension at different lengths of gestation. 
The associations between the different hypertensive disorders and fetal death were 
estimated as RRs, by applying log-link models for binary data. Also changes in the 
proportions of stillborn infants by maternal hypertensive disorder from 1967-1986 to 
1987-2006 were estimated. 
Results The prevalence of hypertensive disorders in pregnancy was 4.7%. In total 
17,933 fetal deaths occurred and 9.2% of these were in hypertensive pregnancies. In 
normotensive pregnancies 0.8% (16 290/2 022 400) experienced fetal death. That 
was true for 1.9% (1 170/62 261) of the pregnancies with pre-eclampsia, 1.2% 
(390/32 068) with gestational hypertension and 1.8% (83/4 642) with chronic 
hypertension. There was a 44% overall reduction in the fetal mortality rate from 1967-
1986 to 1987-2006. The largest decline was in women with pre-eclampsia (80% 
reduction). In women with gestational hypertension and chronic hypertension the 
overall reduction in fetal mortality rates was 49% and 57% respectively, comparable 
to the 41% decline in normotensive pregnancies.  
Conclusion In our nationwide study during 1967-2006 the risk of fetal death among 
women with hypertensive disorders in pregnancy was greatly reduced, especially 
among pre-eclamptic women at term.  
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8. DISCUSSION 
The main findings in this thesis are:  
1. Maternal PVB infection was not found to be significantly associated with fetal 
death. PVB infection does not seem to have any sizeable contribution to the 
overall risk of fetal death, since only four of 281 cases of fetal death were 
infected.  
2. The risk of fetal death in Norway has been reduced by nearly 70% in 
pregnancies lasting longer than 22 weeks during 1967-2006, however, at 16-
22 weeks of gestation, an increase in risk was observed.  
3. Women 40 years old or older had the highest risk of fetal death throughout 
pregnancy, particularly in term and post-term pregnancies. However, the risk 
associated with high maternal age was attenuated in recent times. 
4. In our nationwide study during 1967-2006, the risk of fetal death among 
women with hypertensive disorders in pregnancy was shown to be greatly 
reduced, especially among pre-eclamptic women at term. The risk of fetal 
death among women with gestational or chronic hypertension decreased, but 
in a different manner 
In the following sections the methods used in the thesis are briefly discussed (the 
individual Papers contain more in-depth considerations). Thereafter the individual 
results of the Papers included in the thesis are discussed. 
8.1 Methodological considerations
Epidemiological studies are conducted with the purpose to achieve reliable and valid 
estimates of the association between exposures and disease. Imprecision of 
estimates are caused by random error and improvement is generally achieved by 
increasing the sample size. CIs are computed to assess the precision of point 
estimates, thus the narrower the CI the more precise is the estimate.  
The validity of epidemiological studies has two aspects: internal and external validity. 
Internal validity relates to the inference of the estimates to the study population.  
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Internal validity is impaired in epidemiological studies by selection bias, information 
bias and confounding. High internal validity is a requirement for external validity, 
which relates to inference beyond the study population.255
Sample size considerations 
Paper I Fetal death and PVB infection in pregnancy are rare events; hence a case-
control design was chosen in Paper I. The reported lack of association between PVB 
infection and fetal death in our study may be due to sample size limitations (type 2 
error), as indeed numbers were limited in the sub-analysis (only 4 cases among 281 
were PVB-positive by serology). In our study, 17 women among 957 controls had 
either IgM in the first serum sample or seroconverted. It was estimated that 
approximately 9000 women (cases + controls) would be needed in the study to 
detect a OR of 1.5 with 80% power using a two-sided 5% test.256;257  
Papers II-IV In Papers II-IV we utilized population-based data from the MBRN (>2 
million births and >17 000 fetal deaths). By utilizing this resource, we were able to 
study the rare outcome of fetal death with limited random error and narrow 
confidence intervals.  
Selection bias 
Selection bias is caused by systematic error in the selection process of the study 
sample, leading to a different association of exposures and outcomes in participants 
relative to non-participants.255
Paper I In Paper I, we conducted a case-control study within the nationwide 
prospective Toxoplasmosis Study. In this study the risk of selection bias was limited, 
as cases were all fetal deaths occurring in the cohort of 35 940 pregnant women who 
had participated in the Toxoplasmosis Study.242 The exact participation rate is not 
known, but is assumed to be very high judging by the number of live births in the 11 
participating counties.242 Controls were randomly selected among all women in the 
Toxoplasmosis Study cohort delivering a live-born child at the end of follow-up, thus 
assuring that the exposure distribution of controls reflected the exposure distribution 
in the source population for cases.  
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Selection bias may also be considered due to incomplete/losses to follow-up of 
initially seronegative women (n=442) in the Toxoplasmosis Study cohort. These 
women did not have IgG antibodies against PVB in the first serum sample and 
therefore were at risk of seroconversion, but 68 of these women did not have follow-
up serum available, and therefore PVB seroconversion could not be determined. This 
could cause biased estimates if the association between PVB infection and fetal 
death differed among women lost to follow-up compared to women with more than 
one serum sample collected. However, there were 25 cases of fetal death among 
these women, and for nine of these women the lack of follow-up was according to 
Toxoplasmosis Study protocol, as they had IgG antibodies against T. gondii in the 
first trimester. We do not believe that this would bias our estimates, as we only 
encountered 10 seroconversions among 372 susceptible women, and it is unlikely 
that lack of follow-up or presence of antibodies against T.gondii is associated with an 
increased risk of PVB infection.  
The study has limited generalizability beyond the Norwegian study population, as the 
seroprevalence of IgG (35%-81%) and seroconversion rate among pregnant women 
has been reported to vary across countries, and genetic susceptibility may be 
different as well.243  
Papers II-IV In Papers II-IV we conducted population-based retrospective cohort 
studies using the MBRN, which comprises information on all live births and fetal 
deaths from 16 weeks of gestation in Norway, hence selection bias was limited. 
Fetal deaths are prone to underreporting in vital registries,258 however, temporal 
increases in early fetal deaths (birth weight <500 g corresponding to approximately 
20-22 weeks of gestation) due to better registration have been reported.259 Potential 
increased registration of early fetal deaths in the MBRN in recent time could have 
biased our results, causing some of the observed association between period (year) 
and early fetal death in Paper II. In Paper III, however, the results are not likely to be 
biased as registration of early fetal death is not associated with maternal age.  
Information bias 
Information bias occurs when the obtained information about exposure or outcome is 
erroneous (misclassification). Misclassification can be non-differential, that is, 
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unrelated to other variables, while differential misclassification differs according to 
other study variables.255
Paper I In Paper I the risk of information bias for the exposure (maternal antibody 
status) was low, as maternal antibody status was determined by serological testing in 
the laboratory. The kits used for detection of antibodies have a high specificity, and 
retesting of borderline positive sera was performed to further increase the specificity. 
Moreover, as serum samples were prospectively collected (prior to birth outcome), 
any potential misclassification of PVB infection according to fetal vital status would be 
non-differential, leading to attenuation of the association. Non-differential 
misclassification of a dichotomous explanatory variable causes bias in the estimates 
toward the null value.255
Another potential source of non-differential misclassification for the exposure may be 
due to the timing of the serum sampling. After infection there is a serological window 
of approximately 7 days where IgM and IgG are not detectable. IgM then rises and is 
detectable from day 7-10 and then decreases during 2-3 moths, whereas IgG is 
detectable only after 2 weeks.260 If the women acquired PVB infection prior to 
pregnancy, but had persistent IgM at the time of serum sampling, they may have 
been erroneously categorized as having an acute infection, whereas women infected 
shortly prior to serum sampling may erroneously be categorized as un-infected.  
Information on outcome (fetal death or live birth) was obtained from the MBRN. 
Notification of these outcomes to the MBRN is reported to be good,38 and the high 
quality of information in the MBRN is maintained by routine linkage to other 
population registries, and comprehensive quality assurance.6 However, as previously 
mentioned, before 1999 some elective pregnancy terminations (due to serious 
congenital anomalies) may have been misclassified as fetal death, which may 
underestimate the association between fetal death and PVB infection in our study. 
According to a national study, the estimated induced abortion rate after 16 weeks of 
gestation in Norway in 1996-1997 was 2-3 per 1000 births, and induced abortions 
were seldom performed after 21 weeks of gestation.261 The fetal mortality rate at >16 
weeks of gestation in the MBRN was 9-10 per 1000 births during the same period.1 In 
our study 25% of fetal deaths occurred before 21 weeks of gestation (25% of 283 
74
fetal deaths),262 hence between 14-23 fetal deaths (<21 weeks of gestation) (that is 
2-3 induced abortions per 9-10 fetal deaths) could potentially have been 
misclassified. 
Fetal death occurring at the lower limit of registration (16 weeks of gestation) may 
have been underestimated if the women were not hospitalized or if the length of 
gestation was uncertain. The impact of this bias is probably low and independent of 
the exposure (PVB). 
Papers II-IV In all three papers fetal death was the main outcome measure. This 
variable has not been validated in the MBRN, but the diagnosis of unexplained 
antepartum fetal death (>28 weeks) has been validated in the registry, and has been 
reported to have high validity,263 as have several other validated variables in the 
registry.264-269  
As formerly stated, some elective pregnancy terminations (due to serious congenital 
anomalies) during 1986-1998 could have been differentially misclassified as fetal 
death. This would cause a falsely increased rate of fetal death between 16-20 weeks 
of gestation, since induced abortions were seldom performed after 21 weeks of 
gestation after the implementation of ultrasound examinations in antennal care during 
1986.261 This may have biased the association between early fetal death and period 
(1986-1998) in Paper II. Indeed the highest risk of early fetal death (gestational 
weeks 16-22) was observed during 1992-1996, though the risk remained significantly 
increased during the most recent period (2002-2006) as well.  
High maternal age is associated with a higher number of pregnancy terminations due 
to the increased risk of malformations or anomalies detected at prenatal ultrasound 
examinations.71 Hence, the observed association of early fetal death and high 
maternal age in Paper III may be overestimated. This was further explored by 
repeating analysis including births during 1999-2006 only. The analysis 
demonstrated an attenuated HR of fetal death among women aged 40-44 years 
(relative to women aged 20-24 years) at gestational weeks 16-22 (Appendix I, Table 
A). 
75
Misclassification of gestational age could have biased our results in Paper II-IV. 
Gestational age estimations were based on the women’s reporting of the first day of 
her LMP during 1967-1998, whereas from 1999 ultrasound dating was available in 
the MBRN.6 LMP could cause inaccurate determination of length of gestation in 
women with irregular menstrual cycles, or uncertain first day of LMP. Studies 
comparing the accuracy of ultrasound and LMP to estimate gestational age have 
reported higher incidence of post term (>42 weeks) births when LMP is applied, 
whereas there were only minor discrepancies in the prediction of preterm (<37 
weeks) and term births.270;271  
This could have caused biased estimates in Paper II, however, any overestimation of 
post-term pregnancies caused by applying LMP to predict term (before 1999) would 
underestimate, rather than overestimate, the reduction in fetal death post term in the 
later time period (1987-2006). 
As misclassification of gestational age estimations is probably not differential 
according to maternal age or hypertensive disorders in pregnancy, the results in 
Paper III-VI are most likely not biased.  
In Paper IV, maternal hypertensive disorders in pregnancy were studied, however, 
only pre-eclampsia has been validated previously (reporting positive predictive value 
of 64%-88%).272 Blood pressure measurements and urine examinations are an 
essential part of the Norwegian public antenatal care program, and clinical findings 
are registered in the standard antenatal form that the women bring to the hospital at 
the time of delivery. As compulsory notification of birth to the MBRN is made on 
standardized forms shortly after delivery, differential misclassification due to recall 
bias or according to vital status of the infant is probably low. However, non-
differential misclassification is more likely and would attenuate the association 
between exposure and outcome in the study. 
Although the diagnostic criteria for hypertensive disorders in pregnancy have 
remained nearly unchanged,272 the registration of hypertensive disorders may have 
become more complete (less frequently misclassified) after 1998, when the MBRN 
introduced a new form with pre-coded check boxes regarding maternal hypertensive 
disorders. This would most likely not differentially affect any one type of hypertensive 
disorder,273;274 or differ according to fetal vital status. 
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Confounding 
Confounding, or mixing of effects, occurs when the effect of an exposure on the 
outcome is distorted by a confounding variable. The confounding variable is 
associated both with the exposure and outcome (but is not an effect of outcome or 
exposure) (Figure 9). Figure 9 depicts a causal diagram of confounding, with the 
confounder being a common cause of both the exposure and the outcome variable. 
Known confounders can be dealt with at the analysis stage of the study, e.g. by 
including it as an explanatory variable in multivariable regression models, or by 
stratification, given that this variable has been measured.255
Figure 9. Causal diagram with Confounding
In Paper I the association between maternal PVB infection and fetal death could be 
confounded by maternal age58;243 and parity,60;244 hence, effect estimates were 
adjusted for these risk factors.  
Residual confounding refers to the distortion that remains after adjustment for 
confounders, and is due to additional confounding factors that were either not 
considered or not available.275 Data on potential confounders such as maternal 
stress276;277 and SES170;244 were not available, and thus their contribution could not 
be assessed. However, previous studies have indicated that parity/number of 
children in the household has a stronger association with seroconversion (exposure) 
in susceptible women compared to other risk factors.244
PVB Fetal death 
Maternal age
Risk factor Fetal death 
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In Paper II we adjusted for maternal age, parity, multiple pregnancies, paternal age 
and pre-eclampsia, as these risk factors are associated both with the explanatory 
variable (period) and outcome (fetal death). Other risk factors were not adjusted for 
either because we lacked information on the variable or because no confounding 
effect was suspected. 
In Papers II-III we adjusted the risk estimates for the confounding effect of multiple 
pregnancies (plurality) whereas in Paper IV multiple pregnancies were excluded from 
the sample. In retrospect, the latter approach is preferable as multiple pregnancies 
differ in many aspects from singletons pregnancies; multiple pregnancies are more 
susceptible to low birth weight, short gestational age, higher perinatal mortality, and 
have an increased risk of complications during delivery.278 In the study sample of 
Papers II-III, only 2.7% were multiple pregnancies, and subsequently exclusion of 
multiple pregnancies from did not significantly alter the risk estimates (Appendix I, 
Table B and C).     
We lacked information on maternal BMI, smoking, SES and ethnicity, and thus where 
not able to control for the effect of these factors.  
Maternal BMI is associated with risk of fetal death36;83 and varies by calendar period 
(year),279 thus BMI may have biased our results. However, as high BMI is associated 
with fetal death and the prevalence of high BMI in our population has increased, our 
estimates of temporal declines in the rate of fetal death may be underestimates. In 
Paper III, BMI is a potential mediator associated with both the outcome (fetal death) 
and the explanatory variable (maternal age).280 Since BMI is differentially associated 
with advanced gestation,92 the observed increased risk of fetal death as gestation 
advances among older women may partly be explained by BMI. In Paper IV, as 
hypertensive disorders in pregnancy are associated with BMI,281 the observed risk of 
fetal death may represent overestimates. 
In Papers II and III we did not adjust for maternal diabetes or hypertensive disorders 
in pregnancy (apart from pre-eclampsia). Diabetes55;69 and hypertensive 
disorders13;248 are associated with an increased risk of fetal death, and as the 
prevalence of these disorders has increased,1 our estimates may be deflated. In 
Paper III we did not adjust for these risk factors, as they were perceived as mediators 
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of the association between maternal age and fetal death, and as such should not be 
adjusted for (Figure 10).  
  
Figure 10. Causal diagram with Mediator
In Papers II-III we did not test for interaction between exposures and confounders as 
we had no reason to believe that it would influence fetal death at different gestational 
lengths. This assumption was subsequently explored by conducting analysis of 
gestational-age-specific risk of fetal death according to maternal age stratified by 
parity (Appendix I, Table D). This exercise revealed that the detrimental effect of high 
maternal age on risk of fetal death is more pronounced among nulliparous than 
multiparous women. However, within each strata high maternal age was associated 
with an increased risk of fetal death. 
8.2 Interpretation of the results 
8.2.1 Maternal human parvovirus B19 infection and risk of fetal death 
The main aim of Paper I was to asses the association between maternal PVB 
infection (serological confirmed) and risk of fetal death (>16 weeks of gestation) in 
the Norwegian population. In our study maternal PVB infection was not associated 
with fetal death, as the proportion of pregnant women exposed to PVB infection did 
not differ among cases and controls (presence of IgM: crude OR 0.76, 95% CI 0.16-
3.52; seroconversion: crude OR 1.18, 95% CI 0.25-5.70). In addition, maternal PVB 
Maternal age Fetal death 
Hypertension
Risk factor Fetal death 
Mediator 
79
antibody status was not significantly associated with gestational age or birth weight. 
There are several possible explanations for the lack of association in our study:  
1) In our population PVB was not significantly associated with fetal death.  
2) Our study is underpowered to find an association.  
3) Lack of complete follow-up/under ascertainment. 
4) Low diagnostically accuracy.  
Since the first case reports in the early 1980s,282 several large prospective cohort 
studies of pregnant women with serologically-confirmed PVB infection have shown 
an increased risk of fetal death of 5-11%,218;219;283;284 whereas others did not report 
an increased risk.285;286 The increased fetal mortality rate reported by some of these 
studies could be due to inclusion of pregnant women with symptoms of PVB 
infection, as being symptomatic may be associated with more severe infection. This 
is supported by the recent prospective cohort study by Bonvicini and colleagues, who 
reported higher PVB IgM and DNA values in symptomatic women compared to 
women with PVB infection discovered during routine screening (asymptomatic).287
Hence, some of the association reported in these studies may be due to the selection 
of symptomatic women (non-representative sample). In one of the first large 
prospective studies of PVB serology positive women (n=190), 11% of the women 
who experienced a fetal loss had >1 prior stillbirth compared to only 1% among 
women with live birth.218 Thus some of the increased risk of fetal death in PVB 
seropostive women could be due to factors other than PVB infection. We included all 
cases of fetal death from a large population-based cohort, hence, the risk of selection 
bias was limited and we also had a representative control group for comparison.
PVB IgG antibodies were present in the first serum sample of 64% of the women, 
rendering 36% susceptible to infection. This is comparable to previous 
reports.276;285;288-290 Among 442 susceptible women 21 had serological signs of 
infection (4.8%). Previous studies have reported seroconversion rates among 
susceptible pregnant women during endemic periods between 0.6%-1.5% and during 
epidemic period up to 13.5%.244;276;289  
Higher risk of fetal demise has been reported when maternal PVB infection occurs at 
<20 gestational weeks,218;219;287 with most fetal deaths occurring between 13-20 
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weeks of gestation.218;219;291 The increased vulnerability at early gestational ages is 
explained by the increased expression of P-antigen receptor in the trophoblast during 
the first and second trimesters, whereas it is missing in the third trimester. This 
receptor is utilized by PVB for transplacental transfer, followed by destruction of 
erythroid precursors that may cause severe fetal anemia. The anemic fetus may 
develop hydrops fetalis, which is associated with increased risk of fetal death, 
although most cases resolve spontaneously.243 Recently, Weiffenbach and 
colleagues proposed that increased vulnerability prior to 20 weeks of gestation, may 
be due to limited transfer of maternal IgG across the placenta to the fetus, coupled 
with a poor fetal antibody response, by which the fetuses ability to control the 
infection is impaired.292  
As we only included cases of fetal death >16 weeks of gestation, early fetal deaths 
associated with PVB were excluded, but also some cases >16 weeks may have been 
missed if the women were not hospitalized. Thus low ascertainment may have 
caused attenuation of the association.   
Three Swedish studies reported PVB infection to be a common cause of non-
hydropic fetal death in the third trimester.220;223;224 Tolfvenstam and colleagues 
examined 47 cases of fetal death (>22 weeks of gestation).224 Seven of the cases 
(15%) and none of the healthy controls were PVB DNA-positive. However, PVB DNA 
was detected in different specimens among cases (placental or fetal tissue) and 
controls (placental tissue). The suitability of placentas from live births as control 
material has been questioned.219 The majority of fetuses (n=5) were non-hydropic 
and no specific organ manifestation was detected, and maternal serology was 
negative. It remains unclear if these findings are spurious, or if the differing clinical 
picture presents manifestations of PVB-related late fetal death. The authors 
speculated that the pathophysiological mechanism involved in the third trimester may 
be different than in the second trimester, and may involve persistent low-grade 
infection and placental dysfunction.293 If PVB is a common cause of late fetal deaths 
occurring in PVB seronegative women, we may have underestimated the number of 
fetal deaths associated with PVB. However, others have questioned the Swedish 
studies.294;295 Recently Riipinen and colleagues retrospectively studied 169 cases of 
late fetal death (>22 weeks), and only detected PVB DNA in four cases (2.4%).295
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Detection methods for maternal PVB infection may be direct (PCR) or by serology. In 
our study serological testing was utilized to confirm maternal infection, as this 
diagnostic method has high specificity and sensitivity. Molecular techniques for the 
detection of the viral genome by PCR have an even higher sensitivity, but 
contamination can also increase the number of false-positives. Thus it is possible 
that we missed some cases of fetal death caused by PVB, as we did not use the 
most reliable diagnostic methods: serology in combination with PCR.287;296
PVB is not a common cause of fetal death in the Norwegian population, but for the 
time being, PVB investigation should remain a part of the work-up after fetal death, 
as some fetal death may be caused by PVB, and for a grieving couple, knowing the 
cause of fetal death can have immense value.  
8.2.2 Trends in fetal death in Norway 
The main aim of this paper was to study temporal trends and gestational-age-specific 
changes in fetal death. We reported a significant reduction in the fetal mortality rate 
(>22 weeks) during 1967-2006. The largest absolute decline was in pregnancies at 
term (>37 weeks), however, for pregnancies at 16-22 weeks an opposite trend was 
observed.  
The majority of high-income countries (Sweden, Denmark, Norway, Iceland, France, 
Spain, Italy, the United Kingdom, the Netherlands, Wales, the United States) have 
reported declining trends in fetal death, from 25-45 fetal deaths (>28 weeks) per 
1000 births in 1940, to 3-5 per 1000 births in the year 2000,233 and between 1.5-4.3 
per 1000 births in 2009.44 In the United States the fetal mortality rate (>20 weeks) 
was reported to have declined from 18.4 per 1000 births in 1950 to 6.2 per 1000 in 
2005.297 This trend is likely explained by improvements in general public health and 
in maternity care. In Norway, all pregnant women are offered routine antenatal 
examinations free of charge and the attendance rate is high (>99%).298 A Norwegian 
cross-sectional study by Backe reported that the mean number of antenatal visits 
increased slightly from the 1980s to 1996, and a follow-up study reported a similar 
number of antenatal visits in 2000 (mean=12).298 In addition, advances in obstetric 
services, such as routine ultrasound, extensive use of cardiotocography, induction of 
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labor and the increased caesarean section rate, has contributed to the success of 
modern obstetrics. 
The European project for monitoring and evaluating perinatal outcomes on the 
European level (EURO-PERISTAT Project) estimated fetal mortality rates from 
European countries/regions in 2004 and 2009, and reported large inter-country 
differences in fetal mortality rates (>22 weeks), from 2.6 to 9.1 per 1000 in 2004 and 
from 4 to 8 per 1000 in 2009.43;44 Differences were most likely due to differing 
registration policies, inclusion of pregnancy terminations in some countries and 
differing prevalence of risk factors and perinatal care. Hence the underlying causes 
of the observed trends are best studied at the national level.299  
In our study the fetal mortality rate varied according to length of gestation, and the 
largest absolute decline occurred in term pregnancies (>37 weeks). This trend has 
been confirmed by others,300;301 and may be attributed increased fetal surveillance 
and intervention at term. Indeed, some of the racial inequality in stillbirth at term in 
the United States was linked to Black women being less likely to undergo induction 
compared to non-Hispanic Whites.24;239 Willinger and colleagues demonstrated that 
women with medical conditions, such as diabetes or hypertensive disorders in 
pregnancy, have an increased risk of fetal death at term (week 37-41), and exclusion 
of women with these conditions from their analysis reduced the hazard of fetal death 
by 5-10%.24 Thus some of the decline in late stillbirths in our population may be due 
to close monitoring and timely delivery of women with medical conditions. 
Postponement of childbearing may also contribute to increased risk at term and post 
term, as reported in Paper III and other studies.23;65;66 The hazard of fetal death at 
term declined further when we adjusted for maternal age and preeclampsia, as both 
risk factors have increased in our population. We lacked information on BMI, 
smoking, ethnicity and SES, which may have a differential impact on term births. A 
recent study from Norway demonstrated that the effect of social inequality on 
offspring mortality was lowest at term and post term (week 37-43), and increased 
during preterm gestation and 1 week after birth.302 The authors attributed the 
observed risk reduction to equal access to public health care.  
During our extensive observation time (1967-2006) the method for the estimation of 
term date has changed: during 1967-1998 it was based on LMP, but from 1999 it was 
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based on ultrasound examinations. The proportion of post term pregnancies may 
have been overestimated before the introduction of ultrasound;271 however, any 
overestimation of post term pregnancies due to the use of LMP to predict term may 
have underestimated the temporal reduction in term fetal mortality. 
Contrary to the reduction in fetal death at term, we report an almost doubled fetal 
mortality rate at 16-22 weeks of gestation in 2002-2006 compared to 1967-1971. This 
observation could be due to increased registration or the observed trend is real and 
merits further investigation. 
Increased case ascertainment over time may be a possible explanation for our 
findings; however, increased risk of fetal death at early gestation has been confirmed 
by other studies.11;23;24 Joseph and colleagues conducted a retrospective cohort 
study of births in British Columbia during 2000-2010, and reported an increasing 
number of stillbirths with a birth weight <500 g, which was largely attributed to 
pregnancy terminations due to congenital anomalies.11 However, even after 
exclusion of pregnancy terminations, the rate of fetal death at early gestation 
exceeded the rate in mid-gestation (week 28-36). Compared to spontaneous fetal 
death with birth weight >1000g, which declined significantly during 2000-2010, fetal 
deaths with birth weight <500 g declined non-significantly. Similarly, Martin and 
colleagues reported a declining trend in late fetal mortality at >28 weeks of gestation 
in the United States, but a steady fetal mortality rate at 20-27 weeks of gestation.301
However, after 1999 our data did not include pregnancy terminations.      
Our findings could reflect a true increase, and some of this increase may be due to 
the advancing age of childbearing women. This is supported by the observed 
attenuation of the risk of fetal death in gestational week 16-22 when adjustment for 
maternal age was performed (in 2002-2006, crude RR 2.05 vs. adjusted RR 1.87). 
Reddy and colleagues also reported an increased risk of fetal death at early 
gestation among older women.23
This reported trend could also be caused by a higher number of women undergoing 
treatment with excisional cervical surgery due to cervical intraepithelial neoplasia, as 
this treatment increases the risk of perinatal mortality and extreme preterm delivery 
with intrapartum death as a consequence.303 In Norway, the proportion of 
childbearing women treated with excisional cervical surgery increased more than 20-
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fold between the periods 1967-1979 and 2000-2003, and cumulative incidence of 
treatment is higher among older women.304 Another possible cause of the increased 
fetal mortality rate could be infections, as infections are assumed to be related to 
fetal death at early gestation.  
Willinger and colleagues reported that women with certain pregnancy risk factors 
(incompetent cervix, premature rupture of membranes, uterine bleeding, 
hypertensive disorders in pregnancy) have an increased risk of fetal death at early 
gestation (week 20-27), and demonstrated that exclusion of women with these 
conditions from their analysis reduced the hazard of fetal death by 15-22%.24   
The perinatal mortality rate is a quality parameter of obstetric and neonatal care, 
hence it is important to study temporal trends to evaluate interventions and 
healthcare services delivered. Variations in gestational-age-specific fetal death may 
reveal further differences in registration practice and quality of care.  
8.2.3 The impact of maternal age and fetal death 
The aim of Paper III was to assess the association of maternal age with fetal death 
by gestational age and by time period by applying the fetuses-at-risk model. We 
reported an increased risk of fetal death with advancing maternal age throughout 
pregnancy; the risk was particularly increased in early gestation, and as pregnancy 
progressed to term and past term the increased risk in older women intensified.  
An association between high maternal age and increased risk of fetal death has been 
reported in several studies.36;305 The mechanisms involved remain uncertain, as the 
increased risk may be attenuated, but not completely explained, by medical 
conditions,50;60 uteroplacental insufficiency,306 high BMI or low SES.62 In two recent, 
large population-based studies from the United States and the United Kingdom, 
when only non-anomalous deliveries were included in the study the association 
between maternal age and stillbirth risk disappeared.69;70 However, our estimates did 
not change when we repeated our analysis excluding deliveries with congenital 
anomalies.      
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In a recent multi-center case-control study from Italy, of 254 fetal deaths (cases) and 
497 live births (controls), maternal age >35 years was not associated with increased 
risk of fetal death. BMI >25 was the only risk factor significantly associated with fetal 
death at term (OR 7.70, 95% CI 2.9-20.5).307 Hence, in some populations the 
increased risk of fetal death in older mothers may be explained by an increased 
prevalence of overweight and obesity. Carolan and colleagues conducted a 
systematic review of advanced maternal age and adverse perinatal outcome.305 The 
review included nine studies (>40 million women), but only one study adjusted for 
maternal BMI, and after adjustment the increased risk of perinatal mortality in women 
35-39 years old was no longer significant (adjusted OR 1.1, 95% CI 0.6-1.9). 
However, the risk in women >40 years was still increased (adjusted OR 2.2, 95% CI 
1.1-4.5).308 As we lacked information of maternal BMI in the registry, we were not 
able to adjust for this confounding factor. 
The reported increased risk among older mothers at gestational week 16-22 could be 
due to: a) increased registration of early fetal losses by time (years), b) a true 
increase that may be caused by higher cumulative incidence of treatment with 
excisional cervical surgery. Both alternatives are likely to contribute, as studies from 
other high-income countries have reported increased registration of fetal deaths 
weighing <500 g.259 However, under-registration of these fetuses is also of 
concern,258 hence our high estimate in the last time period may be an underestimate 
rather than an overestimate.  
As already mentioned, the proportion of childbearing women treated with excisional 
cervical surgery increased more than 20-fold in Norway during 1967-2003, and 
cumulative incidence of treatment is higher among older women.304 This treatment 
increases the risk of perinatal mortality (RR 2.08, 95% CI 1.04-4.13) and extreme 
preterm delivery (<28 weeks, RR 13.00, 95% CI 1.70-99.12) with intrapartum death 
as a consequence.303;309  
Our reported association between advanced maternal age and risk of fetal death at 
term and post term is in accordance with several recent studies.23;64-66 Uteroplacental 
insufficiency has been proposed as a possible link between maternal age and fetal 
death at late gestational age,57 whereas others have rejected this.306  
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Interestingly, the impact of maternal age on the risk of fetal death at term and post 
term was attenuated in the most recent time period 1987-2006 compared to 1967-
1986. This is most likely due to a “cohort effect”. During the last decades, vast 
advances in antenatal and obstetric care have occurred, which may have benefited 
older women and enabled safe delivery. Our observations are supported by the 
declining rates of post term births in Norway (the proportion of women giving birth in 
week 42 declined from 9.4% in 1967 to 3.8% in 2012) and the increase in the 
caesarean section rate (1.8% in 1967 to 16.3% in 2006).1 Herstad and colleagues 
analyzed population-based Norwegian data for 1999-2006 and reported a 
significantly higher incidence of elective caesarean section in low-risk women >40 
years old relative to women aged 20-24 years (RR 11.7, 95% CI 8.9-15.4).310  
The other possible explanation is “the healthy mother effect”, i.e. older childbearing 
women in recent times may be healthier and better-educated than mothers of the 
same age 40 year ago. Data from the EURO-PERISTAT project support this 
theory.311 Wide variations in the proportion of childbearing women >35 years old 
across 12 European countries were reported, from 7.4% in Estonia to 21.9% in 
Ireland. The association between high maternal age and risk of fetal death decreased 
as the prevalence of childbearing women aged >35 years increased in the 
populations studied. The authors proposed two possible explanations for this: a) 
higher SES among older childbearing women, b) adaptation of clinical practice in 
countries with a high prevalence of older pregnant women.  
In the last period (1987-2006) we observed an increased risk of fetal death among 
women aged <20 years old (HR 1.77, 95% CI 1.20-2.60) in gestational weeks 38-39. 
This observation may be explained by increased immigration in Norway during the 
last decades. Ethnic background has been related to teenage pregnancies and an 
increased risk of fetal death.183;312 This observation was further confirmed when 
additional analyses were conducted, limiting the study period 1999-2006, and 
demonstrated a significant increased risk of fetal death at gestational weeks 16-22 
and 37-43 among women aged <20 years relative to women aged 20-24 years 
(Appendix I, Table A). 
Results from prior studies diverge regarding the risk of fetal death among young 
women. A recent study reported an increased risk of fetal death among women 16 
years of age (adjusted RR 1.37, 95% CI 1.09-1.7) and women 18 years of age 
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(adjusted RR 1.17, 95% CI 1.04-1.30) relative to 20-year-old women.73 The authors 
hypothesized that childbearing young women in recent times may have a more 
disadvantageous risk profile (low SES, high BMI, increased prevalence of smoking) 
than older women. 
8.2.4 Hypertensive disorders in pregnancy and risk of fetal death 
The main aim of Paper IV was to study and compare the association between 
different hypertensive disorders in pregnancy and fetal death.  
The prevalence of hypertensive disorders in our study was: preeclampsia 2.9%, 
gestational hypertension 1.5% and chronic hypertension 0.5%. The prevalence of 
gestational hypertension and chronic hypertension were lower than those reported in 
other studies, as the prevalence of gestational hypertension is reported to be 2-3% 
and approximately 0.5-2% for chronic hypertension.109;248 Hence, these diseases 
may have been under reported in the registry, and may attenuate the association. As 
the “normotensive” population is large misclassification of hypertensive disorders 
would not have affected the prevalence in this group. 
Our study demonstrated an increased risk of fetal death in women with pre-
eclampsia (RR 2.3), gestational hypertension (RR 1.5), and chronic hypertension 
(RR 2.1) relative to normotensive women during the study period 1967-2006. 
Previous studies in Norway only reported on preeclampsia.102;114 During the 40 years 
studied, the stillbirth rate among women with any hypertensive disorder in pregnancy 
declined, but the largest decline was observed in women with preeclampsia. This 
decline is likely due to the changes in the organization and execution of antenatal 
care. In 1983, a committee appointed by the government of Norway developed the 
“Maternal healthcard” and systematic guidelines regarding antenatal care. Early 
detection and timely delivery of infants at increased risk of fetal death likely 
contributed to the reported decline.102 Klungsøyr and colleagues reported an 
increased proportion of preeclamptic singleton pregnancies delivered by caesarean 
section (RR 3.0) and induced labor (RR 1.3) during 1967-2008 in Norway.114 Similar 
trends have been reported by several studies from high-income 
countries.70;110;115;117;307 Cruz and colleagues conducted a retrospective cohort study 
88
including 12 723 pregnant women with hypertensive disorders, and reported 
significantly more fetal deaths in the control group (defined by the absence of past 
and present medical conditions). The authors hypothesized that this may be due to 
higher rates of induction of labor prior to the event of fetal death.117 Facchinetti and 
colleagues reported pre-eclampsia to be a protective factor in modern maternity care 
(OR 0.4, 95% CI 0.2-0.8), attributing this to increased alertness to the clinical 
presentation of this disorder, and to extensive access to antenatal care.307  
A decline in the risk of stillbirth among women with gestational hypertension and 
chronic hypertension was also observed, but to a lesser extent than for 
preeclampsia. This may be due to improved registration after implementation of the 
new notification form with pre-coded check boxes in 1999, or to less clinical alertness 
and intervention on the part of healthcare professionals in these women compared to 
preeclamptic pregnancies. This could also be due to the demographic change in 
Norway during the study period, with increased incidence of pregnancies among 
women of advanced age and non-Western women. Women with chronic 
hypertension are more likely to be either older, Black or to have diabetes,110;117 and a 
high rate of stillbirth is reported among women with both chronic hypertension and 
diabetes mellitus due to a proposed additive effect of these conditions.111   
We studied the gestational-age-specific risk of fetal death among women with 
hypertensive disorders, and reported an increased risk as pregnancy advanced 
relative to normotensive pregnancies, with the highest RR at term and post-term. 
This may imply that the mechanism involved in the increased risk of fetal death is 
placental dysfunction.115 This is further supported by the increased risk of SGA 
infants in hypertensive pregnancies.248 Helgadottir and colleagues studied 377 cases 
of fetal death occurring in two hospitals in Norway during 1990-2003, and observed 
that the risk of fetal death in hypertensive pregnancies was mediated by SGA infants, 
as the risk of fetal death among pregnant women with hypertensive disorders but 
without a SGA infant was only moderately increased .53  
In the later period 1987-2006, a paradoxical relationship between preeclampsia and 
gestational-age-specific fetal death was observed, with a higher risk among 
preeclamptic pregnancies compared to normotensive pregnancies at term, but a 
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lower risk or protective effect of preeclampsia in early gestation. This observation 
could be true or spurious. 
Infants delivered preterm due to preeclampsia may have a more favorable outcome 
than the control group of infants delivered preterm for other pathological causes, 
such as infection.313  
Yet another possibility is the potentially increased survival advantage among fetuses 
in preeclamptic pregnancies, due to an increased level of maternal cortisol, which 
may lead to expedited lung maturation.248   
When studying fetal death at early gestation by applying the conventional method to 
estimate risk, we conditioned on birth and in this case, preterm birth. However, 
according to knowledge obtained from direct acyclic graphs (DAG), gestational age is 
a collider, a common effect, and conditioning on a collider (collider stratification) may 
cause spurious effects to occur, or even reversal of the association (Figure 11).314
Preeclampsia is associated with fetal death, and preterm birth is a common effect, 
therefore conditioning on births (and not all ongoing pregnancies) introduces bias, 
and may cause reversal of the association from increased risk to a protective effect 
(personal communication with Dr. Allen J. Wilcox). This can be avoided by applying 
the fetus-at-risk model, but this was not possible within the present data, as 
gestational age at preeclampsia occurrence is not registered in the MBRN.  
Figure 11. Causal diagram with Collider.
However, our choice to apply the conventional model for the estimation of stillbirth 
risk in Paper IV may be justified, as stillbirths and live births could be considered 
competing events. In that case the conventional measure of fetal death risk can be 
interpreted as the ratio between the hazards toward live births and towards stillbirths 
Preeclampsia Fetal death
Preterm birth 
Risk factor Fetal death 
Collider 
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(personal communication with my supervisor Sven Ove Samuelsen). Thus the 
“protective effect” of the exposure (pre-eclampsia), especially around gestational 
weeks 28-35 may be due to a larger impact towards live birth than stillbirth. 
     
The benefit of maternal anti-hypertensive therapy on the risk of fetal death is 
limited.315 Thus, the most efficient means to reduce fetal deaths in pregnant women 
with hypertensive disorders is close clinical follow-up and induction of delivery in 
threatened pregnancies. Our study indicates that pregnant women with hypertensive 
disorders would benefit from closer follow-up near term.  
9. CLINICAL IMPLICATIONS AND FUTURE CHALLENGES  
In conclusion, we showed that: 
PVB infection was not significantly associated with fetal death in our population-
based study. 
The risk of fetal death has significantly declined over the last 40 years in pregnancies 
>22 weeks of gestation, with the absolute largest reduction observed at term (>37 
weeks). However, the risk increased at 16-22 weeks.
Advanced maternal age is associated with increased risk of fetal death in early 
gestation (weeks 16-22) and late gestation (week 37-43); however, in recent years 
the risk associated with age has attenuated. 
Women with disorders in pregnancy have an increased risk of fetal death, however, 
the risk has been greatly reduced during 1967-2006, especially among preeclamtic 
women at term.  
 We speculate that this decline is most likely due to widespread access to free, high-
quality antenatal care and advances in obstetric care.310 The largest decline in fetal 
death in our studies was observed at >37 weeks of gestation, when the gestational-
age-specific risk in most studies is reported to increase, which further supports that 
the decline is due to obstetric intervention.  
The clinical implications of our study are: 
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PVB should remain part of the investigations after fetal death. Even though PVB was 
not significantly associated with fetal death in our study, our study may have been 
underpowered. However, we do not think PVB is a common cause of fetal death in 
our population; hence, investigations should only be performed when indicated by the 
clinical picture. 
Women >35 years have an increased risk of fetal death past term, at which point they 
should be monitored closely. This has already been implemented in the clinic at our 
institution. 
Women with any hypertensive disorders in pregnancy have an increased risk of fetal 
death past term and should be followed with equal vigilance. 
The comprehensive Lancet Stillbirth Series, published in 2011,316 presented priority 
areas for stillbirth prevention in high-income countries, and suggested that to achieve 
further improvement in the future, focus should be placed on specific risk factors and 
specific vulnerable groups. Indeed the largest reductions in fetal death happened 
when intervention strategies were developed and applied for specific causes, such as 
rhesus isoimmunization or implementation of population-based prenatal screening for 
congenital anomalies.10 Hence, to achieve further reductions in fetal death, judicious 
estimates of risk should be made. Research should aim to estimate the gestational-
age-specific risks of fetal death in women with certain risk factors and to estimate the 
effect of interaction between risk factors. 
Maternal overweight and obesity is reported to be the highest ranking modifiable risk 
factor, contributing to nearly 8000 stillbirths per year. Hence there is a need for 
preventive strategies that target this modifiable risk factor. 
Sub-optimal care (both self-care and care delivered by health professionals) has 
been associated with up to 60% of stillbirths, and may explain some of the variation 
in fetal mortality that exists in high-income countries. Racial and ethnic 
disparities,179;317 and social inequalities in fetal mortality170;318 needs to be addressed.  
Recent studies have concluded that pregnancy risk factors known at pregnancy start 
have limited predictive value; hence, future research should explore new risk factors. 
The importance of environmental factors, health care related factors, occupational 
hazards, psychological stress, diet, physical activity need to be further explored.   
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APPENDIX I. 
Table A. Adjusted hazard ratio with 95% CI of fetal death in gestational weeks 16-43 
according to maternal age in the period 1999 to 2006 (corresponding to Table 2 in 
Paper III, but limited to the year 1999 to 2006). 
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Table B. Adjusted hazard ratio with 95% CI of fetal death in gestational weeks 16-43 
according to year of delivery among singletons (corresponding to Table 2 in Paper II, 
but limited to singletons). 
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Table C. Adjusted hazard ratio with 95% CI of fetal death in gestational weeks 16-43 
according to maternal age among singletons (corresponding to Table 2 in Paper III, 
but limited to singletons).
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Table D. Hazard ratio with 95% CI of fetal death in gestational weeks 16-43 
according to maternal age, stratified by parity (corresponding to Table 2 in Paper III, 
but stratified by parity to check for interaction). The P-value was obtained by 
incorporating an interaction term between maternal age and parity into the regression 
model. Nulliparous women 35 years and older had increased risk of fetal death 
compared to multiparous women.  
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Spesifikasjon av skader, neonatale diagnoser og medfødte misdannelser – utfylles av lege
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